% alzhub.org topic: safety % Source: https://alzhub.org/topic/safety % 332 entries, in the order the page lists them. Built from alzhub.org's own records. % 1 entries have no readable author in the source record and carry no author field. @article{schnieder2026-42714614, author = {Schnieder, Marlena}, title = {{[Antibody therapy in Alzheimer's disease]}}, journal = {Zeitschrift fur Gerontologie und Geriatrie}, year = {2026}, doi = {10.1007/s00391-026-02640-8}, pmid = {42714614}, url = {https://doi.org/10.1007/s00391-026-02640-8} } @article{hakim2026-42661728, author = {Hakim, Ryan and Harris, Kristofer and Merrill, Livia and Falk-Vargas, Amanda and Whalen, Eileen and Xia, Tianxu and Ochoa, Olga and Hunter, David and others}, title = {{Real-world evidence for amyloid-targeted therapies: Lecanemab and donanemab}}, journal = {Alzheimer's \& dementia (Amsterdam, Netherlands)}, year = {2026}, doi = {10.1002/dad2.70404}, pmid = {42661728}, url = {https://doi.org/10.1002/dad2.70404} } @article{kang2026-42642841, author = {Kang, Heekyoung and Jang, Hyemin and Ahn, Jehyun and Na, Duk L and Lee, Jae-Hong and Kim, Eun-Joo and Chun, Min Young and Cho, Soo Hyun and others}, title = {{APOE-guided lecanemab dosing dissociates ARIA-E from ARIA-H: The K-ROAD study}}, journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association}, year = {2026}, doi = {10.1002/alz.71765}, pmid = {42642841}, url = {https://doi.org/10.1002/alz.71765} } @article{javed2026-42605139, author = {Javed, Muhammad Nouman and Khan, Saim Mahmood and Mustafa, Smaher and Mujtaba, Amna and Amin, Hassaan and Azhar, Naveen and Hameed, Abdullah and Zayed, Alaa and others}, title = {{Gantenerumab for Early Alzheimer's Disease: An Updated Systematic Review and Meta-Analysis}}, journal = {Brain and behavior}, year = {2026}, doi = {10.1002/brb3.71643}, pmid = {42605139}, url = {https://doi.org/10.1002/brb3.71643} } @article{otomi2026-42507054, author = {Otomi, Yoichi and Shinya, Takayoshi and Otsuka, Hideki and Kasai, Hiroto and Matsushita, Tomoki and Takaoka, Yukiko and Hiroshima, Yuka and Matsubara, Tomoyasu and others}, title = {{Serial amyloid PET demonstrates marked reduction in amyloid burden following donanemab treatment: a real-world cohort study}}, journal = {Japanese journal of radiology}, year = {2026}, doi = {10.1007/s11604-026-02054-x}, pmid = {42507054}, url = {https://doi.org/10.1007/s11604-026-02054-x} } @article{sato2026-a8cec4bf, author = {Sato, K. and Niimi, Y. and Nakashima, S. and Igarashi, A. and Iwata, A. and Kasuga, K. and Nemoto, K. and Higashi, S. and others}, title = {{Protocol for the 2026 Nationwide Survey of Dementia Specialists on the Real-World Implementation of Anti-Amyloid Antibody Therapies in Japan: Clinical Practice, Blood Biomarkers, and Preference Experiments}}, journal = {medRxiv}, year = {2026}, doi = {10.64898/2026.06.30.26356494}, url = {https://doi.org/10.64898/2026.06.30.26356494} } @article{hill2026-16617b5e, author = {Hill, C. and Morgan, H. and Michopoulou, S. and Niranjan, M. and Kipps, C. M.}, title = {{Dynamic Imaging Markers of ARIA-H Risk in the A4 Study: A Person-Interval Analysis of Current Lesion Burden and Recent Microhaemorrhage Activity}}, journal = {medRxiv}, year = {2026}, doi = {10.64898/2026.05.30.26354521}, url = {https://doi.org/10.64898/2026.05.30.26354521} } @article{raket2026-42273802, author = {Raket, Lars L and Lu, Ming and Evans, Cynthia D and Zimmer, Jennifer A and Sparks, JonDavid and Collins, Emily C and Shcherbinin, Sergey and Wang, Hong and others}, title = {{Donanemab treatment effect by baseline tau burden and disease severity: Observations from the TRAILBLAZER-ALZ 2 trial}}, journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association}, year = {2026}, doi = {10.1002/alz.71577}, pmid = {42273802}, url = {https://doi.org/10.1002/alz.71577} } @article{hagiwara2026-40820597, author = {Hagiwara, Akifumi}, title = {{Balancing Speed and Sensitivity: Echo-Planar Accelerated MRI for ARIA-H Screening in Anti-Aβ Therapeutics}}, journal = {Investigative radiology}, year = {2026}, doi = {10.1097/rli.0000000000001232}, pmid = {40820597}, url = {https://doi.org/10.1097/rli.0000000000001232} } @article{mummery2026-41390238, author = {Mummery, Catherine J and Rasmussen, Jill and Blackburn, Dan and Coulthard, Elizabeth and Davies, R Rhys and Dorsey, Rachel and Fox, Nick C and Hosseini, Akram A and others}, title = {{Lecanemab appropriate use recommendations for clinical practice in the UK}}, journal = {Journal of neurology, neurosurgery, and psychiatry}, year = {2026}, doi = {10.1136/jnnp-2025-336597}, pmid = {41390238}, url = {https://doi.org/10.1136/jnnp-2025-336597} } @article{shimasaki2026-41936348, author = {Shimasaki, Ryosuke and Kurihara, Masanori and Bannai, Taro and Hatano, Keiko and Suzuki, Fumio and Tokumaru, Aya Midori and Ishii, Kenji and Ihara, Ryoko and others}, title = {{Amyloid-related imaging abnormalities in Japanese patients with Alzheimer's disease treated with Lecanemab: A real-world study}}, journal = {The journal of prevention of Alzheimer's disease}, year = {2026}, doi = {10.1016/j.tjpad.2026.100562}, pmid = {41936348}, url = {https://doi.org/10.1016/j.tjpad.2026.100562} } @article{qudoos2026-41966037, author = {Qudoos, Muhammad A and Elliott, David P}, title = {{Review of Donanemab and Lecanemab in Mild Dementia Stage of Alzheimer's Disease: Progress and Challenges}}, journal = {The Senior care pharmacist}, year = {2026}, doi = {10.4140/tcp.n.2026.98}, pmid = {41966037}, url = {https://doi.org/10.4140/tcp.n.2026.98} } @article{agosta2026-41857623, author = {Agosta, Federica and Cecchetti, Giordano and Spinelli, Edoardo G and Ghirelli, Alma and Rugarli, Giulia and Pisano, Stefano and Coraglia, Federico and Canu, Elisa and others}, title = {{Real-world implementation of lecanemab and donanemab in an Italian memory center: a 1-year experience}}, journal = {Alzheimer's research \& therapy}, year = {2026}, doi = {10.1186/s13195-026-02015-6}, pmid = {41857623}, url = {https://doi.org/10.1186/s13195-026-02015-6} } @article{guizzaro2026-41852829, author = {Guizzaro, L. and Bałkowiec-Iskra, E. and Haberkamp, M. and Mol, P. G. M. and Moreau, A. and Mueller-Berghaus, J. and Philadelphy, D. and Balabanov, P. and others}, title = {{Balancing benefit and risk in early Alzheimer's disease: the European Medicines Agency (EMA) assessment of lecanemab and donanemab}}, journal = {The Lancet regional health. Europe}, year = {2026}, doi = {10.1016/j.lanepe.2026.101644}, pmid = {41852829}, url = {https://doi.org/10.1016/j.lanepe.2026.101644} } @article{liao2026-41823189, author = {Liao, Wang and Yu, Qun and Chen, Bin and Chen, Hualin and Zou, Liangyu and Xie, Haiqun and Chen, Haobo and Wang, Chenyang and others}, title = {{Effectiveness, safety, and biomarker dynamics of lecanemab in Chinese Alzheimer's disease population: a multicenter real-world study}}, journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association}, year = {2026}, doi = {10.1002/alz.71231}, pmid = {41823189}, url = {https://doi.org/10.1002/alz.71231} } @article{perry2026-41689888, author = {Perry, Richard and Kipps, Christopher and Martín, Maria Eugenia Soto and Bozzali, Marco and Logroscino, Giancarlo and Trafford, Sarah and Dhadda, Shobha and Kanekiyo, Michio and others}, title = {{Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes}}, journal = {The journal of prevention of Alzheimer's disease}, year = {2026}, doi = {10.1016/j.tjpad.2026.100507}, pmid = {41689888}, url = {https://doi.org/10.1016/j.tjpad.2026.100507} } @article{filippi2026-41732200, author = {Filippi, M. and Cecchetti, G. and Spinelli, E. G. and Ghirelli, A. and Rugarli, G. and Pisano, S. and Canu, E. and Agosta, F.}, title = {{Anti-amyloid therapies and the transformation of Alzheimer's care pathways: early lessons from the frontline}}, journal = {The Lancet regional health. Europe}, year = {2026}, doi = {10.1016/j.lanepe.2026.101609}, pmid = {41732200}, url = {https://doi.org/10.1016/j.lanepe.2026.101609} } @article{tariot2026-41579901, author = {Tariot, Pierre N and Lopera, Francisco S and Ríos-Romenets, Silvia and Sink, Kaycee M and Giraldo-Chica, Margarita and Acosta-Baena, Natalia and Villegas, Gustavo and Espinosa, Alejandro and others}, title = {{Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1Glu280Ala mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial}}, journal = {The Lancet. Neurology}, year = {2026}, doi = {10.1016/s1474-4422(25)00426-0}, pmid = {41579901}, url = {https://doi.org/10.1016/s1474-4422(25)00426-0} } @article{jiang2026-41694525, author = {Jiang, Xiangxiang and Lv, Gang and Mendes, Morgan E and Wu, Jun and Yuan, Jing and Lu, Z Kevin}, title = {{Lifetime cost-effectiveness of lecanemab for early Alzheimer's disease}}, journal = {Frontiers in public health}, year = {2026}, doi = {10.3389/fpubh.2026.1692508}, pmid = {41694525}, url = {https://doi.org/10.3389/fpubh.2026.1692508} } @article{rezaii2026-4202aa20, author = {Rezaii, N. and Dickson, JR. and Ford, J. N. and He, Y. and Katsumi, Y. and Ramirez-Gomez, L. and Lam, A. and Shah, H. and others}, title = {{Real-World Characterization of Amyloid-Related Imaging Abnormalities (ARIA) in Lecanemab Treatment at an Academic Health System}}, journal = {medRxiv}, year = {2026}, doi = {10.64898/2026.01.23.26344739}, url = {https://doi.org/10.64898/2026.01.23.26344739} } @article{tziakouri2026-41567052, author = {Tziakouri, Andria and Loser, Valentin and Vicino, Alex and Baumgartner, Thomas and Di Liberto, Giovanni and Pantazou, Vasiliki and Bernard-Valnet, Raphaël and Theaudin, Marie and others}, title = {{[Neurology : what's new in 2025]}}, journal = {Revue medicale suisse}, year = {2026}, doi = {10.53738/revmed.2026.22.946.48114}, pmid = {41567052}, url = {https://doi.org/10.53738/revmed.2026.22.946.48114} } @article{higgins2026-41596530, author = {Higgins, M. and Wasef, V. and Kwakowsky, A.}, title = {{FDA-Approved Passive Immunization Treatments Against Aβ in Alzheimer's Disease: Where Are We Now?}}, journal = {International journal of molecular sciences}, year = {2026}, doi = {10.3390/ijms27020883}, pmid = {41596530}, url = {https://doi.org/10.3390/ijms27020883} } @article{solfrizzi2026-41428477, author = {Solfrizzi, Vincenzo and Imbimbo, Bruno P}, title = {{Comparing clinical effect sizes of SouvenaidTM, lecanemab, and donanemab in early Alzheimer's disease}}, journal = {Journal of Alzheimer's disease : JAD}, year = {2026}, doi = {10.1177/13872877251406221}, pmid = {41428477}, url = {https://doi.org/10.1177/13872877251406221} } @article{godugu2025-41562774, author = {Godugu, Deepika and Gattu, Kranthi and Suri, Parul and Daartey, Abel B and Jadhav, Krishna and Rojekar, Satish}, title = {{Nanobody Therapeutics in Alzheimer's Disease: From Molecular Mechanisms to Translational Approaches}}, journal = {Antibodies (Basel, Switzerland)}, year = {2025}, doi = {10.3390/antib15010001}, pmid = {41562774}, url = {https://doi.org/10.3390/antib15010001} } @article{leng2026-41396015, author = {Leng, L. and Liao, Z. and Lu, P. and Sun, Y. and Weng, Q. and Fan, W. and Zhu, H. and Wu, W. and others}, title = {{Real-world experience with baseline characteristics and safety of lecanemab for Alzheimer's disease in Eastern China}}, journal = {Journal of Alzheimer's disease : JAD}, year = {2026}, doi = {10.1177/13872877251406619}, pmid = {41396015}, url = {https://doi.org/10.1177/13872877251406619} } @article{shim2026-41352683, author = {Shim, G. H. and Lau, E. C. Y. and Huynh, A. L. H. and Lu, C. Y. and Tan, E. C. K.}, title = {{Influence of patient characteristics on efficacy and safety of anti-amyloid monoclonal antibodies in Alzheimer's disease: A systematic review and meta-analysis}}, journal = {Ageing research reviews}, year = {2026}, doi = {10.1016/j.arr.2025.102981}, pmid = {41352683}, url = {https://doi.org/10.1016/j.arr.2025.102981} } @article{noguchishinohara2025-41276859, author = {Noguchi-Shinohara, M. and Yoshinobu, T. and Ozaki, T. and Muramatsu, D. and Shima, A. and Sakashita, Y. and Tada, Y. and Yamaguchi, H. and others}, title = {{Higher phosphorylated tau levels predict cognitive decline and amyloid-related imaging abnormalities during lecanemab treatment: clinical practice data}}, journal = {Alzheimer's research \& therapy}, year = {2025}, doi = {10.1186/s13195-025-01912-6}, pmid = {41276859}, url = {https://doi.org/10.1186/s13195-025-01912-6} } @article{rabiei2025-41271757, author = {Rabiei, K. and Petrella, JR. and Lenhart, S. and Liu, C. and Hao, W. and {Alzheimer Disease Neuroimaging Initiative}}, title = {{Data-driven modeling of amyloid-β targeted antibodies for Alzheimer's disease}}, journal = {NPJ systems biology and applications}, year = {2025}, doi = {10.1038/s41540-025-00610-1}, pmid = {41271757}, url = {https://doi.org/10.1038/s41540-025-00610-1} } @article{shang2025-41250246, author = {Shang, Jia and Zhong, Siyan and Shang, Li and Zeng, Qingze and Zhao, Shuai and Luo, Xiao and Li, Kaicheng and Zhang, Xinyi and others}, title = {{Real-world application of lecanemab in early-stage alzheimer's disease: a single-center prospective cohort analysis}}, journal = {Alzheimer's research \& therapy}, year = {2025}, doi = {10.1186/s13195-025-01886-5}, pmid = {41250246}, url = {https://doi.org/10.1186/s13195-025-01886-5} } @article{lopepiedrafita2025-343d96ed, author = {Lope-Piedrafita, S. and Serra-Mir, G. and Melón, P. and Bonaterra, A. and Hernández-Guillamon, M. and Villegas, S.}, title = {{ScFv-h3D6 Prevents Bapineuzumab-Induced Hemorrhagic Events in the APP23 Mouse Model of Alzheimer’s Disease}}, journal = {Preprints.org}, year = {2025}, doi = {10.20944/preprints202511.0180.v1}, url = {https://doi.org/10.20944/preprints202511.0180.v1} } @article{llibreguerra2025-41184455, author = {Llibre-Guerra, Jorge J and McDade, Eric M and Schindler, Suzanne E and Clifford, David B and Supnet, Charlene and Atri, Alireza and Bateman, Randall J}, title = {{Towards pharmacological prevention of Alzheimer disease}}, journal = {Nature reviews. Neurology}, year = {2025}, doi = {10.1038/s41582-025-01154-y}, pmid = {41184455}, url = {https://doi.org/10.1038/s41582-025-01154-y} } @article{jeon2025-41225766, author = {Jeon, So Yeon and Byun, Min Soo and Choi, Hye Ji and Kim, Yoon Hee and Gwag, Chung Hee and Oh, Yoonseok and Park, Jee Eun and Yi, Dahyun and others}, title = {{Eligibility for lecanemab and donanemab in Korea under Appropriate Use Recommendations}}, journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association}, year = {2025}, doi = {10.1002/alz.70875}, pmid = {41225766}, url = {https://doi.org/10.1002/alz.70875} } @article{guo2025-41107537, author = {Guo, X. and Yue, R. and Cui, Z. and Wang, S. and Jia, T. and Li, W. and Zhang, W. and Shan, L. and others}, title = {{Advances of therapeutic strategies for Alzheimer's disease}}, journal = {Journal of neurology}, year = {2025}, doi = {10.1007/s00415-025-13456-8}, pmid = {41107537}, url = {https://doi.org/10.1007/s00415-025-13456-8} } @article{elamin2025-41077117, author = {Elamin, S. A. and Al Shibli, A. N. and Shaito, A. and Al-Maadhadi, M. J. M. B. and Zolezzi, M. and Pedersen, S.}, title = {{Anti-amyloid monoclonal antibody therapies in Alzheimer's disease - a scoping review}}, journal = {Neuroscience}, year = {2025}, doi = {10.1016/j.neuroscience.2025.10.011}, pmid = {41077117}, url = {https://doi.org/10.1016/j.neuroscience.2025.10.011} } @article{schreiber2025-41042497, author = {Schreiber, C. P. and Kovacik, A. and Bishop, J. and Helman, J.}, title = {{Amyloid-related Imaging Abnormalities (ARIA) in the Context of Alzheimer's Disease and Amyloid-targeting Therapies: An Introduction for Advanced Practice Providers}}, journal = {Drugs \& aging}, year = {2025}, doi = {10.1007/s40266-025-01253-x}, pmid = {41042497}, url = {https://doi.org/10.1007/s40266-025-01253-x} } @article{curd2025-b62fc105, author = {Curd, B. C. and Zubrick, C. and Cliatt Brown, C. J. and Sorweid, M. K. and Dehoney, S. B. and Anzai, Y. and Minoshima, S. and Parks, A. L. and others}, title = {{Real-world experience with lecanemab therapy for Alzheimer’s disease in the Intermountain West}}, journal = {medRxiv}, year = {2025}, doi = {10.1101/2025.09.30.25337002}, url = {https://doi.org/10.1101/2025.09.30.25337002} } @article{chen2025-41070709, author = {Chen, S. and Ou, R. and Wei, Q. and Li, C. and Song, W. and Zhao, B. and Yang, J. and Fu, J. and others}, title = {{Lecanemab treatment for Alzheimer's Disease of varying severities and associated plasma biomarkers monitoring: A multi-center real-world study in China}}, journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association}, year = {2025}, doi = {10.1002/alz.70750}, pmid = {41070709}, url = {https://doi.org/10.1002/alz.70750} } @article{chu2025-41057989, author = {Chu, C. and Ma, L. and Wang, Y. and Huynh, A. L. H. and Dunstan, M. K. and Cui, X. and Masters, C. L. and Goudey, B. and others}, title = {{Predicting severity of cerebral amyloid angiopathy neuropathology: A modeling approach using NACC and ROSMAP data}}, journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association}, year = {2025}, doi = {10.1002/alz.70057}, pmid = {41057989}, url = {https://doi.org/10.1002/alz.70057} } @article{pascuallucas2025-41058018, author = {Pascual-Lucas, M. and Lacosta, A. M. and Montañés, M. and Canudas, J. and Loscos, J. and Monleón, I. and Allué, J. A. and Sarasa, L. and others}, title = {{Safety, tolerability, immunogenicity, and efficacy of ABvac40 active immunotherapy against Aβ40 in patients with mild cognitive impairment or very mild Alzheimer's disease: A randomized, double-blind, placebo-controlled phase 2 study}}, journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association}, year = {2025}, doi = {10.1002/alz.70776}, pmid = {41058018}, url = {https://doi.org/10.1002/alz.70776} } @article{papaliagkas2025-41096797, author = {Papaliagkas, Vasileios T.}, title = {{Anti-Amyloid Therapies for Alzheimer’s Disease: Progress, Pitfalls, and the Path Ahead}}, journal = {International Journal of Molecular Sciences}, year = {2025}, doi = {10.3390/ijms26199529}, pmid = {41096797}, url = {https://doi.org/10.3390/ijms26199529} } @article{jaeger2025-377d6a5b, author = {Jaeger, J. and Staats, K. A. and Barnum, S. and Pope, P. and Kingery, L. and Buitendyk, M. and Cohen, S. and Tansey, M. G. and others}, title = {{XPro1595, a Selective Soluble TNF Neutralizer, in Early Alzheimer’s Disease with Inflammation (ADi): Results from the Phase 2 MINDFuL Trial}}, journal = {medRxiv}, year = {2025}, doi = {10.1101/2025.09.24.25336496}, url = {https://doi.org/10.1101/2025.09.24.25336496} } @article{sharma2025-40993929, author = {Sharma, Chanchal and Mazumder, Avijit}, title = {{From Bench to Bedside: Cutting-Edge and Emerging Therapies for Alzheimer's Disease}}, journal = {Central nervous system agents in medicinal chemistry}, year = {2025}, doi = {10.2174/0118715249388723250910140541}, pmid = {40993929}, url = {https://doi.org/10.2174/0118715249388723250910140541} } @article{francis2025-40940304, author = {Francis, E. and Paylor, S. and Van, C. and Mathews, B. and Sobhanian, M. J. and Mansour, D. Z. and Hennawi, G. and Brandt, N. J.}, title = {{Review of anti-amyloid-beta (Aβ) monoclonal antibodies for the treatment of Alzheimer's disease}}, journal = {Expert review of clinical pharmacology}, year = {2025}, doi = {10.1080/17512433.2025.2556122}, pmid = {40940304}, url = {https://doi.org/10.1080/17512433.2025.2556122} } @article{alkhalifa2025-41003140, author = {Alkhalifa, A. E. and Al Mokhlf, A. and Ali, H. and Al-Ghraiybah, N. F. and Syropoulou, V.}, title = {{Anti-Amyloid Monoclonal Antibodies for Alzheimer's Disease: Evidence, ARIA Risk, and Precision Patient Selection}}, journal = {Journal of personalized medicine}, year = {2025}, doi = {10.3390/jpm15090437}, pmid = {41003140}, url = {https://doi.org/10.3390/jpm15090437} } @article{saido2025-40899945, author = {Saido, Takaomi C and Iwata, Nobuhisa}, title = {{The tale of donanemab: God is in the details}}, journal = {Journal of Alzheimer's disease : JAD}, year = {2025}, doi = {10.1177/13872877251371240}, pmid = {40899945}, url = {https://doi.org/10.1177/13872877251371240} } @article{yaari2025-40955720, author = {Yaari, Roy and Holdridge, Karen C and Williamson, Melissa and Wessels, Alette M and Shcherbinin, Sergey and Kotari, Vikas and Reiman, Eric M and Tariot, Pierre N and others}, title = {{Donanemab in preclinical Alzheimer's disease: Screening and baseline data from TRAILBLAZER-ALZ 3}}, journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association}, year = {2025}, doi = {10.1002/alz.70662}, pmid = {40955720}, url = {https://doi.org/10.1002/alz.70662} } @article{pereiradasilva2025-40692324, author = {Pereira da Silva, A. M. and Falcão, L. and Virgilio, F. and Rodrigues Menezes, I. and Leite, M. and Farias, E. and Nascimento, M. and Lee Han, M. and others}, title = {{Efficacy and APOE ε4-stratified risk of donanemab in Alzheimer's disease: A systematic review and meta-analysis of randomized clinical trials}}, journal = {Journal of Alzheimer's disease : JAD}, year = {2025}, doi = {10.1177/13872877251361044}, pmid = {40692324}, url = {https://doi.org/10.1177/13872877251361044} } @article{arai2025-40708311, author = {Arai, Heii and Aiba, Satoko and Arai, Reiko}, title = {{Safety of switching from lecanemab to donanemab in 20 consecutive patients with Alzheimer's disease}}, journal = {Journal of Alzheimer's disease : JAD}, year = {2025}, doi = {10.1177/13872877251361051}, pmid = {40708311}, url = {https://doi.org/10.1177/13872877251361051} } @article{gupta2025-40884704, author = {Gupta, Arushi and Pahal, Sonu and Kumar, Vivek and Chaudhary, Amit}, title = {{Role of Monoclonal Antibodies in Alzheimer's Disease: Successes, Failures, and Future Directions}}, journal = {Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology}, year = {2025}, doi = {10.1007/s10072-025-08456-5}, pmid = {40884704}, url = {https://doi.org/10.1007/s10072-025-08456-5} } @article{dodel2025-40790925, author = {Dodel, Richard and Frölich, Lutz}, title = {{Donanemab for Alzheimer's disease: from preclinical research to the clinical application}}, journal = {Expert review of neurotherapeutics}, year = {2025}, doi = {10.1080/14737175.2025.2546868}, pmid = {40790925}, url = {https://doi.org/10.1080/14737175.2025.2546868} } @article{sabbagh2025-40782673, author = {Sabbagh, Marwan Noel and Kennedy, Jessica and Majeed, Jad and Decourt, Boris}, title = {{Alzheimer's disease: Clinical trials to watch}}, journal = {Med (New York, N.Y.)}, year = {2025}, doi = {10.1016/j.medj.2025.100771}, pmid = {40782673}, url = {https://doi.org/10.1016/j.medj.2025.100771} } @article{pizzo2025-40773560, author = {Pizzo, M. E. and Plowey, E. D. and Khoury, N. and Kwan, W. and Abettan, J. and DeVos, S. L. and Discenza, C. B. and Earr, T. and others}, title = {{Transferrin receptor-targeted anti-amyloid antibody enhances brain delivery and mitigates ARIA}}, journal = {Science (New York, N.Y.)}, year = {2025}, doi = {10.1126/science.ads3204}, pmid = {40773560}, url = {https://doi.org/10.1126/science.ads3204} } @article{hardy2025-40739944, author = {Hardy, John}, title = {{Alzheimer's Disease: Treatment Challenges for the Future}}, journal = {Journal of neurochemistry}, year = {2025}, doi = {10.1111/jnc.70176}, pmid = {40739944}, url = {https://doi.org/10.1111/jnc.70176} } @article{wang2025-40624486, author = {Wang, Y. and Yu, Q. and Chen, B. and Zhou, J. and Li, Z. and Liao, W. and Liu, J. and Yang, A.}, title = {{Two cases of Amyloid-Related Imaging Abnormalities (ARIA) following lecanemab treatment for alzheimer's disease and a literature review}}, journal = {BMC neurology}, year = {2025}, doi = {10.1186/s12883-025-04302-5}, pmid = {40624486}, url = {https://doi.org/10.1186/s12883-025-04302-5} } @article{wang2025-40619285, author = {Wang, Hong and Nery, Emel Serap Monkul and Ardayfio, Paul and Khanna, Rashna and Svaldi, Diana Otero and Shcherbinin, Sergey and Xu, Wen and Andersen, Scott W and others}, title = {{The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6}}, journal = {The journal of prevention of Alzheimer's disease}, year = {2025}, doi = {10.1016/j.tjpad.2025.100266}, pmid = {40619285}, url = {https://doi.org/10.1016/j.tjpad.2025.100266} } @article{mccullough2025-40660741, author = {McCullough, Austin and Chen, Charles D and Gordon, Brian A and Joseph-Mathurin, Nelly and Jack, Clifford R and Koeppe, Robert and Hornbeck, Russ and Koudelis, Deborah and others}, title = {{Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN-TU-001 trial}}, journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association}, year = {2025}, doi = {10.1002/alz.70347}, pmid = {40660741}, url = {https://doi.org/10.1002/alz.70347} } @article{yang2025-40650049, author = {Yang, H. M.}, title = {{Recent Advances in Antibody Therapy for Alzheimer's Disease: Focus on Bispecific Antibodies}}, journal = {International journal of molecular sciences}, year = {2025}, doi = {10.3390/ijms26136271}, pmid = {40650049}, url = {https://doi.org/10.3390/ijms26136271} } @article{loi2025-40550741, author = {Loi, Samantha M and Kang, Matthew Jy}, title = {{Donanemab: The dawn of disease-modifying treatment for Alzheimer's disease in Australia}}, journal = {Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists}, year = {2025}, doi = {10.1177/10398562251355157}, pmid = {40550741}, url = {https://doi.org/10.1177/10398562251355157} } @article{chundu2025-40621323, author = {Chundu, U. C. and Thiriveedhi, SR. and Bhatti, C. and Mupparaju, J. S. and Otinashvili, N. and Gelishvili, E.}, title = {{A Systematic Review of the Efficacy and Safety of Anti-amyloid Monoclonal Antibodies in Alzheimer's Disease}}, journal = {Cureus}, year = {2025}, doi = {10.7759/cureus.85377}, pmid = {40621323}, url = {https://doi.org/10.7759/cureus.85377} } @article{cummings2025-40463637, author = {Cummings, Jeffrey L and Zhou, Yadi and Lee, Garam and Zhong, Kate and Fonseca, Jorge and Leisgang-Osse, Amanda M and Cheng, Feixiong}, title = {{Alzheimer's disease drug development pipeline: 2025}}, journal = {Alzheimer's \& dementia (New York, N. Y.)}, year = {2025}, doi = {10.1002/trc2.70098}, pmid = {40463637}, url = {https://doi.org/10.1002/trc2.70098} } @article{su2025-40473116, author = {Su, Ching-Hui and Chang, Ying-Tzu and Tseng, Huan-Shu and Kuo, Chan-Yen and Chen, Jin-Hua and Chien, Po-Yu and Chang, Yao-Jen and Hung, Chin-Chuan}, title = {{Comparisons of efficacy and safety of immunotherapies for Alzheimer's disease treatment: A network meta-analysis of randomised controlled trials}}, journal = {Clinical medicine (London, England)}, year = {2025}, doi = {10.1016/j.clinme.2025.100336}, pmid = {40473116}, url = {https://doi.org/10.1016/j.clinme.2025.100336} } @article{kong2025-40520157, author = {Kong, L. and Yang, X. and Xu, J.}, title = {{Comparison of safety of lecanemab and aducanumab: a real-world disproportionality analysis using the FDA adverse event reporting system}}, journal = {Frontiers in pharmacology}, year = {2025}, doi = {10.3389/fphar.2025.1593989}, pmid = {40520157}, url = {https://doi.org/10.3389/fphar.2025.1593989} } @article{bregman2025-40437535, author = {Bregman, N. and Nathan, T. and Shir, D. and Omer, N. and Levy, M. H. and David, A. B. and Aizenstien, O. and Lotan, E. and others}, title = {{Lecanemab in clinical practice: real-world outcomes in early Alzheimer's disease}}, journal = {Alzheimer's research \& therapy}, year = {2025}, doi = {10.1186/s13195-025-01763-1}, pmid = {40437535}, url = {https://doi.org/10.1186/s13195-025-01763-1} } @article{sehlin2025-40425446, author = {Sehlin, D. and Hultqvist, G. and Michno, W. and Aguilar, X. and Dahlén, A. D. and Cerilli, E. and Bucher, N. M. and Lopes van den Broek, S. and others}, title = {{Bispecific brain-penetrant antibodies for treatment of Alzheimer's disease}}, journal = {The journal of prevention of Alzheimer's disease}, year = {2025}, doi = {10.1016/j.tjpad.2025.100214}, pmid = {40425446}, url = {https://doi.org/10.1016/j.tjpad.2025.100214} } @article{giannakis2025-40393205, author = {Giannakis, Alexandros and Konitsiotis, Spiridon}, title = {{Anti-Amyloid Agents: A Self-Fulfilling prophecy}}, journal = {Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia}, year = {2025}, doi = {10.1016/j.jocn.2025.111338}, pmid = {40393205}, url = {https://doi.org/10.1016/j.jocn.2025.111338} } @article{terao2025-40386876, author = {Terao, Itsuki and Kodama, Wakako}, title = {{Comparative efficacy, tolerability, and acceptability of aducanumab, lecanemab, and donanemab with repetitive transcranial magnetic stimulation on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis}}, journal = {Journal of psychopharmacology (Oxford, England)}, year = {2025}, doi = {10.1177/02698811251340901}, pmid = {40386876}, url = {https://doi.org/10.1177/02698811251340901} } @article{pikus2025-40361247, author = {Pikus, P. and Turner, R. S. and Rebeck, G. W.}, title = {{Mouse models of Anti-Aβ immunotherapies}}, journal = {Molecular neurodegeneration}, year = {2025}, doi = {10.1186/s13024-025-00836-x}, pmid = {40361247}, url = {https://doi.org/10.1186/s13024-025-00836-x} } @article{rosenbloom2025-40355750, author = {Rosenbloom, M. and Schnee, A. and Nimma, S. and Lutz, H. and Gzesh, D. and Weisman, D.}, title = {{Monoclonal antibody administration in an academic institution and private neurological practice: a tale of two clinics}}, journal = {Journal of neurology}, year = {2025}, doi = {10.1007/s00415-025-13142-9}, pmid = {40355750}, url = {https://doi.org/10.1007/s00415-025-13142-9} } @article{kutzsche2025-40324978, author = {Kutzsche, J. and Cosma, N. C. and Kauselmann, G. and Fenski, F. and Bieniek, C. and Bujnicki, T. and Pils, M. and Bannach, O. and others}, title = {{Oral PRI-002 treatment in patients with MCI or mild AD: a randomized, double-blind phase 1b trial}}, journal = {Nature communications}, year = {2025}, doi = {10.1038/s41467-025-59295-z}, pmid = {40324978}, url = {https://doi.org/10.1038/s41467-025-59295-z} } @article{hsu2025-40316479, author = {Hsu, C. W. and Hsu, T. W. and Kao, Y. C. and Lin, Y. H. and Thompson, T. and Carvalho, A. F. and Stubbs, B. and Tseng, P. T. and others}, title = {{The efficacy and safety of anti-amyloid monoclonal antibody versus acetylcholinesterase inhibitor with an in-depth analysis across genotypes and disease stages: a systematic review and meta-analysis}}, journal = {The journal of prevention of Alzheimer's disease}, year = {2025}, doi = {10.1016/j.tjpad.2025.100195}, pmid = {40316479}, url = {https://doi.org/10.1016/j.tjpad.2025.100195} } @article{salloway2025-40390253, author = {Salloway, S. and Pain, A. and Lee, E. and Papka, M. and Ferguson, M. B. and Wang, H. and Hu, H. and Lu, M. and others}, title = {{TRAILBLAZER-ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease}}, journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association}, year = {2025}, doi = {10.1002/alz.70293}, pmid = {40390253}, url = {https://doi.org/10.1002/alz.70293} } @article{seifert2025-40281535, author = {Seifert, Rebecca M and Klingebiel, Randolf and Schäbitz, Wolf-Rüdiger}, title = {{Diagnosis, pathomechanisms and therapy of cerebral amyloid angiopathy-related inflammation (CAA-ri)}}, journal = {Neurological research and practice}, year = {2025}, doi = {10.1186/s42466-025-00382-3}, pmid = {40281535}, url = {https://doi.org/10.1186/s42466-025-00382-3} } @article{besin2025-40951730, author = {Besin, Valentinus and Humardani, Farizky Martriano and Yudiarto, Fenny Lanawati and Ong, Paulus Anam and Putra, Sulistyo Emantoko Dwi and Ningrum, Ratih Asmana}, title = {{Amyloid-Related Imaging Abnormality (ARIA) Beyond the APOE-ε4 Allele}}, journal = {Chronic diseases and translational medicine}, year = {2025}, doi = {10.1002/cdt3.70006}, pmid = {40951730}, url = {https://doi.org/10.1002/cdt3.70006} } @article{kakeda2025-40266549, author = {Kakeda, S. and Miki, Y. and Kudo, K. and Mori, H. and Tokumaru, A. M. and Abe, O. and Aoki, S. and others}, title = {{Practical brain MRI guidelines for anti-Aβ antibody treatment in early symptomatic Alzheimer's disease}}, journal = {Japanese journal of radiology}, year = {2025}, doi = {10.1007/s11604-025-01773-x}, pmid = {40266549}, url = {https://doi.org/10.1007/s11604-025-01773-x} } @article{mittler2025-40237866, author = {Mittler, Brant and Cambi, Xavier and Biskach, Morgan and Reisman, Joel and Wang, Ying and Berlowitz, Dan and Morin, Peter and Miller, Donald R and others}, title = {{Patient journey and decision processes for anti-amyloid therapy in Alzheimer's disease}}, journal = {Journal of neurology}, year = {2025}, doi = {10.1007/s00415-025-13059-3}, pmid = {40237866}, url = {https://doi.org/10.1007/s00415-025-13059-3} } @article{wang2025-40308765, author = {Wang, H. and Pan, J. and Zhang, M. and Tan, Z.}, title = {{Re-evaluation of the efficacy and safety of anti-Aβ monoclonal antibodies (lecanemab/donanemab) in the treatment of early Alzheimer's disease}}, journal = {Frontiers in pharmacology}, year = {2025}, doi = {10.3389/fphar.2025.1599048}, pmid = {40308765}, url = {https://doi.org/10.3389/fphar.2025.1599048} } @article{ashmawy2025-40232258, author = {Ashmawy, R. E. and Okesanya, O. J. and Ukoaka, B. M. and Daniel, F. M. and Ezedigwe, S. G. and Agboola, A. O. and Ahmed, M. M. and Ogaya, J. B. and others}, title = {{Exploring the efficacy and safety of lecanemab in the management of early Alzheimer's disease: A systematic review of clinical evidence}}, journal = {Journal of Alzheimer's disease : JAD}, year = {2025}, doi = {10.1177/13872877251331640}, pmid = {40232258}, url = {https://doi.org/10.1177/13872877251331640} } @article{rabiei2025-32628a51, author = {Rabiei, K. and Petrella, JR. and Lenhart, S. and Liu, C. and Doraiswamy, P. M. and Hao, W.}, title = {{Data-Driven Modeling of Amyloid-beta Targeted Antibodies for Alzheimer’s Disease}}, journal = {NPJ systems biology and applications}, year = {2025}, doi = {10.21203/rs.3.rs-6316455/v1}, url = {https://doi.org/10.21203/rs.3.rs-6316455/v1} } @article{yan2025-40242445, author = {Yan, L. and Zhang, L. and Xu, Z. and Luo, Z.}, title = {{A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for lecanemab}}, journal = {Frontiers in pharmacology}, year = {2025}, doi = {10.3389/fphar.2025.1559447}, pmid = {40242445}, url = {https://doi.org/10.3389/fphar.2025.1559447} } @article{hu2025-40290431, author = {Hu, H. and Zhao, Y. and Mao, J. and He, J. and Zhang, Y. and Ye, H. and Yang, X.}, title = {{A real-world pharmacovigilance study of adverse drug reactions associated with lecanemab and aducanumab based on WHO-VigiAccess and FAERS databases}}, journal = {Frontiers in pharmacology}, year = {2025}, doi = {10.3389/fphar.2025.1561020}, pmid = {40290431}, url = {https://doi.org/10.3389/fphar.2025.1561020} } @article{asada2025-40302041, author = {Asada, Takashi and Thanasopoulou, Angeliki and Delmar, Paul and Wojtowicz, Jakub and Smith, Janice and Yoshiyama, Yasumasa and Yokoi, Katsunori and Watanabe, Chigusa and others}, title = {{Japanese participant data from three gantenerumab trials in early Alzheimer's disease}}, journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association}, year = {2025}, doi = {10.1002/alz.70192}, pmid = {40302041}, url = {https://doi.org/10.1002/alz.70192} } @article{bateman2025-40120616, author = {Bateman, Randall J and Li, Yan and McDade, Eric M and Llibre-Guerra, Jorge J and Clifford, David B and Atri, Alireza and Mills, Susan L and Santacruz, Anna M and others}, title = {{Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial}}, journal = {The Lancet. Neurology}, year = {2025}, doi = {10.1016/s1474-4422(25)00024-9}, pmid = {40120616}, url = {https://doi.org/10.1016/s1474-4422(25)00024-9} } @article{tonegawakuji2025-40163534, author = {Tonegawa-Kuji, R. and Hou, Y. and Hu, B. and Lorincz-Comi, N. and Pieper, A. A. and Tousi, B. and Leverenz, J. B. and Cheng, F.}, title = {{Efficacy and safety of passive immunotherapies targeting amyloid beta in Alzheimer's disease: A systematic review and meta-analysis}}, journal = {PLoS medicine}, year = {2025}, doi = {10.1371/journal.pmed.1004568}, pmid = {40163534}, url = {https://doi.org/10.1371/journal.pmed.1004568} } @article{cummings2025-40118715, author = {Cummings, Jeffrey L}, title = {{Maximizing the benefit and managing the risk of anti-amyloid monoclonal antibody therapy for Alzheimer's disease: Strategies and research directions}}, journal = {Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics}, year = {2025}, doi = {10.1016/j.neurot.2025.e00570}, pmid = {40118715}, url = {https://doi.org/10.1016/j.neurot.2025.e00570} } @article{bobbins2025-40051090, author = {Bobbins, A. and Davies, M. and Lynn, E. and Roy, D. and Yeomans, A. and Shakir, S. A. W.}, title = {{Safety and effectiveness of the anti-amyloid monoclonal antibody (mAb) drug lecanemab for early Alzheimer's disease: The pharmacovigilance perspective}}, journal = {British journal of clinical pharmacology}, year = {2025}, doi = {10.1002/bcp.70021}, pmid = {40051090}, url = {https://doi.org/10.1002/bcp.70021} } @article{tampi2025-40078953, author = {Tampi, Rajesh R}, title = {{Lecanemab for mild Alzheimer disease - is there a way forward?}}, journal = {Drugs in context}, year = {2025}, doi = {10.7573/dic.2024-12-2}, pmid = {40078953}, url = {https://doi.org/10.7573/dic.2024-12-2} } @article{villain2025-40011173, author = {Villain, N. and Planche, V. and Lilamand, M. and Cordonnier, C. and Soto-Martin, M. and Mollion, H. and Bombois, S. and Delrieu, J. and others}, title = {{Lecanemab for early Alzheimer's disease: Appropriate use recommendations from the French federation of memory clinics}}, journal = {The journal of prevention of Alzheimer's disease}, year = {2025}, doi = {10.1016/j.tjpad.2025.100094}, pmid = {40011173}, url = {https://doi.org/10.1016/j.tjpad.2025.100094} } @article{bittner2025-39887500, author = {Bittner, Tobias and Tonietto, Matteo and Klein, Gregory and Belusov, Anton and Illiano, Vittorio and Voyle, Nicola and Delmar, Paul and Scelsi, Marzia A and others}, title = {{Biomarker treatment effects in two phase 3 trials of gantenerumab}}, journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association}, year = {2025}, doi = {10.1002/alz.14414}, pmid = {39887500}, url = {https://doi.org/10.1002/alz.14414} } @article{kim2025-39865265, author = {Kim, B. H. and Kim, S. and Nam, Y. and Park, Y. H. and Shin, S. M. and Moon, M.}, title = {{Second-generation anti-amyloid monoclonal antibodies for Alzheimer's disease: current landscape and future perspectives}}, journal = {Translational neurodegeneration}, year = {2025}, doi = {10.1186/s40035-025-00465-w}, pmid = {39865265}, url = {https://doi.org/10.1186/s40035-025-00465-w} } @article{greenberg2025-39794509, author = {Greenberg, S. M. and Bax, F. and van Veluw, S. J.}, title = {{Amyloid-related imaging abnormalities: manifestations, metrics and mechanisms}}, journal = {Nature reviews. Neurology}, year = {2025}, doi = {10.1038/s41582-024-01053-8}, pmid = {39794509}, url = {https://doi.org/10.1038/s41582-024-01053-8} } @article{cogswell2025-39179297, author = {Cogswell, P. M. and Andrews, T. J. and Barakos, J. A. and Barkhof, F. and Bash, S. and Benayoun, M. D. and Chiang, G. C. and Franceschi, A. M. and others}, title = {{Alzheimer Disease Anti-Amyloid Immunotherapies: Imaging Recommendations and Practice Considerations for Monitoring of Amyloid-Related Imaging Abnormalities}}, journal = {AJNR. American journal of neuroradiology}, year = {2025}, doi = {10.3174/ajnr.a8469}, pmid = {39179297}, url = {https://doi.org/10.3174/ajnr.a8469} } @article{xing2025-39780222, author = {Xing, X. and Zhang, X. and Wang, K. and Wang, Z. and Feng, Y. and Li, X. and Hua, Y. and Zhang, L. and others}, title = {{Post-marketing safety concerns with lecanemab: a pharmacovigilance study based on the FDA Adverse Event Reporting System database}}, journal = {Alzheimer's research \& therapy}, year = {2025}, doi = {10.1186/s13195-024-01669-4}, pmid = {39780222}, url = {https://doi.org/10.1186/s13195-024-01669-4} } @article{weiner2025-39711072, author = {Weiner, Michael W and Kanoria, Shaveta and Miller, Melanie J and Aisen, Paul S and Beckett, Laurel A and Conti, Catherine and Diaz, Adam and Flenniken, Derek and others}, title = {{Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials}}, journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association}, year = {2025}, doi = {10.1002/alz.14321}, pmid = {39711072}, url = {https://doi.org/10.1002/alz.14321} } @article{arroyopacheco2025-39638097, author = {Arroyo-Pacheco, N. and Sarmiento-Blanco, S. and Vergara-Cadavid, G. and Castro-Leones, M. and Contreras-Puentes, N.}, title = {{Monoclonal therapy with lecanemab in the treatment of mild Alzheimer's disease: A systematic review and meta-analysis}}, journal = {Ageing research reviews}, year = {2025}, doi = {10.1016/j.arr.2024.102620}, pmid = {39638097}, url = {https://doi.org/10.1016/j.arr.2024.102620} } @article{daly2024-39698778, author = {Daly, T. and Olluri, A. and Kurkinen, M.}, title = {{Anti-amyloid treatments in Alzheimer's disease: elegance, evidence and ethics}}, journal = {Advances in clinical and experimental medicine : official organ Wroclaw Medical University}, year = {2024}, doi = {10.17219/acem/198674}, pmid = {39698778}, url = {https://doi.org/10.17219/acem/198674} } @article{geldmacher2024-39620846, author = {Geldmacher, David S}, title = {{Treatment of Alzheimer Disease}}, journal = {Continuum (Minneapolis, Minn.)}, year = {2024}, doi = {10.1212/con.0000000000001503}, pmid = {39620846}, url = {https://doi.org/10.1212/con.0000000000001503} } @article{yang2024-39990823, author = {Yang, Xiyue and Li, Wanting and Yang, Xinglong and Chen, Qin and Li, Hongxia and Lyu, Su and Hu, Na}, title = {{[Radiological Identification and Evaluation of Amyloid-Related Imaging Abnormalities in Alzheimer's Disease]}}, journal = {Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition}, year = {2024}, doi = {10.12182/20241160201}, pmid = {39990823}, url = {https://doi.org/10.12182/20241160201} } @article{hales2025-39893023, author = {Hales, Chadwick M}, title = {{Alzheimer's Disease Diagnosis and Management in the Age of Amyloid Monoclonal Antibodies}}, journal = {The Medical clinics of North America}, year = {2025}, doi = {10.1016/j.mcna.2024.10.003}, pmid = {39893023}, url = {https://doi.org/10.1016/j.mcna.2024.10.003} } @article{heneka2024-39549715, author = {Heneka, Michael T and Morgan, David and Jessen, Frank}, title = {{Passive anti-amyloid β immunotherapy in Alzheimer's disease-opportunities and challenges}}, journal = {Lancet (London, England)}, year = {2024}, doi = {10.1016/s0140-6736(24)01883-x}, pmid = {39549715}, url = {https://doi.org/10.1016/s0140-6736(24)01883-x} } @article{nosheny2024-39535465, author = {Nosheny, Rachel L and Miller, Melanie and Conti, Catherine and Flenniken, Derek and Ashford, Miriam and Diaz, Adam and Fockler, Juliet and Truran, Diana and others}, title = {{The ADNI Administrative Core: Ensuring ADNI's success and informing future AD clinical trials}}, journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association}, year = {2024}, doi = {10.1002/alz.14311}, pmid = {39535465}, url = {https://doi.org/10.1002/alz.14311} } @article{chhabra2024-39432414, author = {Chhabra, Akanksha and Solanki, Siddhant and Saravanabawan, Prithvi and Venkiteswaran, Arun and Nimmathota, NagaTarang and Modi, Nishi Manojkumar}, title = {{A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer's disease}}, journal = {Expert opinion on biological therapy}, year = {2024}, doi = {10.1080/14712598.2024.2416947}, pmid = {39432414}, url = {https://doi.org/10.1080/14712598.2024.2416947} } @article{shir2024-39704652, author = {Shir, Dror and Shiner, Tamara and Bregman, Noa}, title = {{Anti-amyloid treatments for Alzheimer's disease: A study on physicians' perspectives}}, journal = {Journal of Alzheimer's disease : JAD}, year = {2024}, doi = {10.1177/13872877241289788}, pmid = {39704652}, url = {https://doi.org/10.1177/13872877241289788} } @article{park2024-39512702, author = {Park, K. H. and Kim, G. H. and Kim, C. H. and Koh, S. H. and Moon, S. Y. and Park, Y. H. and Seo, S. W. and Yoon, B. and others}, title = {{Lecanemab: Appropriate Use Recommendations by Korean Dementia Association}}, journal = {Dementia and neurocognitive disorders}, year = {2024}, doi = {10.12779/dnd.2024.23.4.165}, pmid = {39512702}, url = {https://doi.org/10.12779/dnd.2024.23.4.165} } @article{avgerinos2024-39468148, author = {Avgerinos, K. I. and Manolopoulos, A. and Ferrucci, L. and Kapogiannis, D.}, title = {{Critical assessment of anti-amyloid-β monoclonal antibodies effects in Alzheimer's disease: a systematic review and meta-analysis highlighting target engagement and clinical meaningfulness}}, journal = {Scientific reports}, year = {2024}, doi = {10.1038/s41598-024-75204-8}, pmid = {39468148}, url = {https://doi.org/10.1038/s41598-024-75204-8} } @article{hunter2024-39443750, author = {Hunter, Philip}, title = {{The controversy around anti-amyloid antibodies for treating Alzheimer's disease : The European Medical Agency's ruling against the latest anti-amyloid drugs highlights the ongoing debate about their safety and efficacy}}, journal = {EMBO reports}, year = {2024}, doi = {10.1038/s44319-024-00294-4}, pmid = {39443750}, url = {https://doi.org/10.1038/s44319-024-00294-4} } @article{shinohara2024-39370836, author = {Shinohara, Moeko and Ono, Kenjiro}, title = {{[Anti-Amyloid Antibody Therapy for Alzheimer's Disease]}}, journal = {Brain and nerve = Shinkei kenkyu no shinpo}, year = {2024}, doi = {10.11477/mf.1416202747}, pmid = {39370836}, url = {https://doi.org/10.11477/mf.1416202747} } @article{rentz2024-39306695, author = {Rentz, D. M. and Aisen, P. S. and Atri, A. and Hitchcock, J. and Irizarry, M. and Landen, J. and Matthews, B. R. and Miller, D. S. and others}, title = {{Benefits and risks of FDA-approved amyloid-targeting antibodies for treatment of early Alzheimer's disease: Navigating clinician-patient engagement}}, journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association}, year = {2024}, doi = {10.1002/alz.14199}, pmid = {39306695}, url = {https://doi.org/10.1002/alz.14199} } @article{thussu2024-39291991, author = {Thussu, S. and Naidu, A. and Manivannan, S. and Grossberg, G. T.}, title = {{Profiling aducanumab as a treatment option for Alzheimer's disease: an overview of efficacy, safety and tolerability}}, journal = {Expert review of neurotherapeutics}, year = {2024}, doi = {10.1080/14737175.2024.2402058}, pmid = {39291991}, url = {https://doi.org/10.1080/14737175.2024.2402058} } @article{gibson2024-39215494, author = {Gibson, A. W. and Elser, H. and Rosso, M. and Cornblath, E. J. and Fonkeu, Y. and Prasad, S. and Rothstein, A. and Nasrallah, I. M. and others}, title = {{Ischemic stroke associated with amyloid-related imaging abnormalities in a patient treated with lecanemab}}, journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association}, year = {2024}, doi = {10.1002/alz.14223}, pmid = {39215494}, url = {https://doi.org/10.1002/alz.14223} } @article{majid2024-39207112, author = {Majid, O. and Cao, Y. and Willis, B. A. and Hayato, S. and Takenaka, O. and Lalovic, B. and Sreerama Reddy, S. H. and Penner, N. and others}, title = {{Population pharmacokinetics and exposure-response analyses of safety (ARIA-E and isolated ARIA-H) of lecanemab in subjects with early Alzheimer's disease}}, journal = {CPT: pharmacometrics \& systems pharmacology}, year = {2024}, doi = {10.1002/psp4.13224}, pmid = {39207112}, url = {https://doi.org/10.1002/psp4.13224} } @article{jeong2024-39109501, author = {Jeong, S. Y. and Suh, C. H. and Kim, S. J. and Lemere, C. A. and Lim, J. S. and Lee, J. H.}, title = {{Amyloid-Related Imaging Abnormalities in the Era of Anti-Amyloid Beta Monoclonal Antibodies for Alzheimer's Disease: Recent Updates on Clinical and Imaging Features and MRI Monitoring}}, journal = {Korean journal of radiology}, year = {2024}, doi = {10.3348/kjr.2024.0105}, pmid = {39109501}, url = {https://doi.org/10.3348/kjr.2024.0105} } @article{vukmir2024-38939962, author = {Vukmir, R. B.}, title = {{Amyloid-related imaging abnormalities (ARIA): diagnosis, management, and care in the setting of amyloid-modifying therapy}}, journal = {Annals of clinical and translational neurology}, year = {2024}, doi = {10.1002/acn3.52042}, pmid = {38939962}, url = {https://doi.org/10.1002/acn3.52042} } @article{hey2024-38902571, author = {Hey, J. A. and Abushakra, S. and Blennow, K. and Reiman, E. M. and Hort, J. and Prins, N. D. and Sheardova, K. and Kesslak, P. and others}, title = {{Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer's Disease}}, journal = {Drugs}, year = {2024}, doi = {10.1007/s40265-024-02067-8}, pmid = {38902571}, url = {https://doi.org/10.1007/s40265-024-02067-8} } @article{menegazdealmeida2024-38879828, author = {Menegaz de Almeida, A. and Leite, M. and Lopes, L. M. and Gomes Lima, P. and Siegloch Barros, M. L. and Rocha Pinheiro, S. and Í, Andrade and Viana, P. and others}, title = {{Gantenerumab for early Alzheimer's disease: a systematic review and meta-analysis}}, journal = {Expert review of neurotherapeutics}, year = {2024}, doi = {10.1080/14737175.2024.2367016}, pmid = {38879828}, url = {https://doi.org/10.1080/14737175.2024.2367016} } @article{hoilundcarlsen2024-38830549, author = {Høilund-Carlsen, Poul F and Alavi, Abass and Barrio, Jorge R and Castellani, Rudolph J and Costa, Tommaso and Herrup, Karl and Kepp, Kasper P and Neve, Rachael L and others}, title = {{Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit}}, journal = {Ageing research reviews}, year = {2024}, doi = {10.1016/j.arr.2024.102348}, pmid = {38830549}, url = {https://doi.org/10.1016/j.arr.2024.102348} } @article{hossain2024-38867460, author = {Hossain, M. F. and Husna, A. U. and Kharel, M.}, title = {{Use of lecanemab for the treatment of Alzheimer's disease: A systematic review}}, journal = {Brain and behavior}, year = {2024}, doi = {10.1002/brb3.3592}, pmid = {38867460}, url = {https://doi.org/10.1002/brb3.3592} } @article{torres2024-39079148, author = {Torres, Astrid and Camargo, Loida and López, Norman}, title = {{Aducanumab: A look two years after its approval}}, journal = {Biomedica : revista del Instituto Nacional de Salud}, year = {2024}, doi = {10.7705/biomedica.6967}, pmid = {39079148}, url = {https://doi.org/10.7705/biomedica.6967} } @article{song2024-38758223, author = {Song, Tanya and Wang, Yunfei and Silverglate, Bret David and Grossberg, George T}, title = {{Pharmacokinetic evaluation of donanemab for the treatment of Alzheimer's}}, journal = {Expert opinion on drug metabolism \& toxicology}, year = {2024}, doi = {10.1080/17425255.2024.2357637}, pmid = {38758223}, url = {https://doi.org/10.1080/17425255.2024.2357637} } @article{soderberg2024-38740836, author = {Söderberg, L. and Johannesson, M. and Gkanatsiou, E. and Nygren, P. and Fritz, N. and Zachrisson, O. and Rachalski, A. and Svensson, A. S. and others}, title = {{Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities}}, journal = {Scientific reports}, year = {2024}, doi = {10.1038/s41598-024-61691-2}, pmid = {38740836}, url = {https://doi.org/10.1038/s41598-024-61691-2} } @article{cummings2024-38659717, author = {Cummings, J. and Zhou, Y. and Lee, G. and Zhong, K. and Fonseca, J. and Cheng, F.}, title = {{Alzheimer's disease drug development pipeline: 2024}}, journal = {Alzheimer's \& dementia (New York, N. Y.)}, year = {2024}, doi = {10.1002/trc2.12465}, pmid = {38659717}, url = {https://doi.org/10.1002/trc2.12465} } @article{chen2024-38567735, author = {Chen, T. and O'Gorman, J. and Castrillo-Viguera, C. and Rajagovindan, R. and Curiale, G. G. and Tian, Y. and Patel, D. and von Rosenstiel, P. and others}, title = {{Results from the long-term extension of PRIME: A randomized Phase 1b trial of aducanumab}}, journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association}, year = {2024}, doi = {10.1002/alz.13755}, pmid = {38567735}, url = {https://doi.org/10.1002/alz.13755} } @article{abdelazim2024-38565747, author = {Abdelazim, K. and Allam, A. A. and Afifi, B. and Abdulazeem, H. and Elbehiry, A. I.}, title = {{The efficacy and safety of lecanemab 10 mg/kg biweekly compared to a placebo in patients with Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials}}, journal = {Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology}, year = {2024}, doi = {10.1007/s10072-024-07477-w}, pmid = {38565747}, url = {https://doi.org/10.1007/s10072-024-07477-w} } @article{geerts2024-38774587, author = {Geerts, H. and Bergeler, S. and Walker, M. and Rose, R. H. and van der Graaf, P. H.}, title = {{Quantitative systems pharmacology-based exploration of relevant anti-amyloid therapy challenges in clinical practice}}, journal = {Alzheimer's \& dementia (New York, N. Y.)}, year = {2024}, doi = {10.1002/trc2.12474}, pmid = {38774587}, url = {https://doi.org/10.1002/trc2.12474} } @article{hoilundcarlsen2024-38612701, author = {Høilund-Carlsen, Poul F and Alavi, Abass and Castellani, Rudolph J and Neve, Rachael L and Perry, George and Revheim, Mona-Elisabeth and Barrio, Jorge R}, title = {{Alzheimer's Amyloid Hypothesis and Antibody Therapy: Melting Glaciers?}}, journal = {International journal of molecular sciences}, year = {2024}, doi = {10.3390/ijms25073892}, pmid = {38612701}, url = {https://doi.org/10.3390/ijms25073892} } @article{yoon2024-38779110, author = {Yoon, C. H. and Groff, C. and Criss, O.}, title = {{Lecanemab: A Second in Class Therapy for the Management of Early Alzheimer's Disease}}, journal = {Innovations in pharmacy}, year = {2024}, doi = {10.24926/iip.v15i1.5787}, pmid = {38779110}, url = {https://doi.org/10.24926/iip.v15i1.5787} } @article{possemis2024-38438923, author = {Possemis, Nina and Verhey, Frans and Prickaerts, Jos and Blokland, Arjan and Ramakers, Inez}, title = {{A proof of concept phase II study with the PDE-4 inhibitor roflumilast in patients with mild cognitive impairment or mild Alzheimer's disease dementia (ROMEMA): study protocol of a double-blind, randomized, placebo-controlled, between-subjects trial}}, journal = {Trials}, year = {2024}, doi = {10.1186/s13063-024-08001-3}, pmid = {38438923}, url = {https://doi.org/10.1186/s13063-024-08001-3} } @article{doggrell2024-38414336, author = {Doggrell, S. A.}, title = {{More failure with solanezumab - this time in preclinical Alzheimer's disease}}, journal = {Expert opinion on biological therapy}, year = {2024}, doi = {10.1080/14712598.2024.2325551}, pmid = {38414336}, url = {https://doi.org/10.1080/14712598.2024.2325551} } @article{qiao2024-38429615, author = {Qiao, Y. and Gu, J. and Yu, M. and Chi, Y. and Ma, Y.}, title = {{Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer's Disease: A Systematic Review and Network Meta-Analysis}}, journal = {CNS drugs}, year = {2024}, doi = {10.1007/s40263-024-01067-2}, pmid = {38429615}, url = {https://doi.org/10.1007/s40263-024-01067-2} } @article{bilodeau2024-38592119, author = {Bilodeau, P. A. and Dickson, JR. and Kozberg, M. G.}, title = {{The Impact of Anti-Amyloid Immunotherapies on Stroke Care}}, journal = {Journal of clinical medicine}, year = {2024}, doi = {10.3390/jcm13051245}, pmid = {38592119}, url = {https://doi.org/10.3390/jcm13051245} } @article{wolters2024-38380503, author = {Wolters, Frank J and Labrecque, Jeremy A}, title = {{Potential impact of unblinding on observed treatment effects in Alzheimer's disease trials}}, journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association}, year = {2024}, doi = {10.1002/alz.13690}, pmid = {38380503}, url = {https://doi.org/10.1002/alz.13690} } @article{park2024-38932758, author = {Park, Kyung Won}, title = {{Anti-amyloid Antibody Therapies for Alzheimer's Disease}}, journal = {Nuclear medicine and molecular imaging}, year = {2024}, doi = {10.1007/s13139-024-00848-3}, pmid = {38932758}, url = {https://doi.org/10.1007/s13139-024-00848-3} } @article{klein2024-38323738, author = {Klein, Eric G and Schroeder, Krista and Wessels, Alette M and Phipps, Adam and Japha, Maureen and Schilling, Traci and Zimmer, Jennifer A}, title = {{How donanemab data address the coverage with evidence development questions}}, journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association}, year = {2024}, doi = {10.1002/alz.13700}, pmid = {38323738}, url = {https://doi.org/10.1002/alz.13700} } @article{doran2024-38312931, author = {Doran, S. J. and Sawyer, R. P.}, title = {{Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications}}, journal = {Frontiers in neuroscience}, year = {2024}, doi = {10.3389/fnins.2024.1326784}, pmid = {38312931}, url = {https://doi.org/10.3389/fnins.2024.1326784} } @article{sato2023-39081988, author = {Sato, K. and Niimi, Y. and Ihara, R. and Suzuki, K. and Iwata, A. and Iwatsubo, T.}, title = {{APOE -ε4 allele[s]-associated adverse events reported from placebo arm in clinical trials for Alzheimer's disease: implications for anti-amyloid beta therapy}}, journal = {Frontiers in dementia}, year = {2023}, doi = {10.3389/frdem.2023.1320329}, pmid = {39081988}, url = {https://doi.org/10.3389/frdem.2023.1320329} } @article{sotoudeh2023-38249159, author = {Sotoudeh, Houman and Alizadeh, Mohammadreza and Shahidi, Ramin and Shobeiri, Parnian and Saadatpour, Zahra and Wheeler, C Austin and Love, Marissa Natelson and Tanwar, Manoj}, title = {{Imaging spectrum of amyloid-related imaging abnormalities associated with aducanumab immunotherapy}}, journal = {Frontiers in radiology}, year = {2023}, doi = {10.3389/fradi.2023.1305390}, pmid = {38249159}, url = {https://doi.org/10.3389/fradi.2023.1305390} } @article{boess2024-38706270, author = {Boess, F G and Scelsi, M A and Grimmer, T and Perry, R J and Tonietto, M and Klein, G and Hofmann, C and Salami, M and others}, title = {{At-Home Administration of Gantenerumab by Care Partners to People with Early Alzheimer's Disease: Feasibility, Safety and Pharmacodynamic Impact}}, journal = {The journal of prevention of Alzheimer's disease}, year = {2024}, doi = {10.14283/jpad.2024.60}, pmid = {38706270}, url = {https://doi.org/10.14283/jpad.2024.60} } @article{toda2024-39350371, author = {Toda, Y. and Iwatsubo, T. and Nakamura, Y. and Matsuda, N. and Miyata, M. and Jin, M. and Chen, T. and Kuribayashi, K. and others}, title = {{Japanese Subgroup Analyses from EMERGE and ENGAGE, Phase 3 Clinical Trials of Aducanumab in Patients with Early Alzheimer's Disease}}, journal = {The journal of prevention of Alzheimer's disease}, year = {2024}, doi = {10.14283/jpad.2024.106}, pmid = {39350371}, url = {https://doi.org/10.14283/jpad.2024.106} } @article{neve2024-39177596, author = {Neve, A. and Das, B. and Wojtowicz, J. and Huang, Z. and Bullain, S. and Watkin, M. and Lott, D. and Bittner, T. and others}, title = {{Long-Term Safety of Gantenerumab in Participants with Alzheimer's Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD)}}, journal = {Journal of Alzheimer's disease : JAD}, year = {2024}, doi = {10.3233/jad-240221}, pmid = {39177596}, url = {https://doi.org/10.3233/jad-240221} } @article{niidome2024-38692883, author = {Niidome, Tetsuhiro and Ishikawa, Yukio and Ogawa, Tomoo and Nakagawa, Masaki and Nakamura, Yosuke}, title = {{[Mechanism of action and clinical trial results of Lecanemab (Leqembi® 200 ‍mg, 500 ‍mg for Intravenous Infusion), a novel treatment for Alzheimer's disease]}}, journal = {Nihon yakurigaku zasshi. Folia pharmacologica Japonica}, year = {2024}, doi = {10.1254/fpj.24005}, pmid = {38692883}, url = {https://doi.org/10.1254/fpj.24005} } @article{espay2024-38701151, author = {Espay, A. J. and Herrup, K. and Imbimbo, B. P. and Kepp, K. P. and Daly, T.}, title = {{Recalibrating the Risk-Benefit Profiles of Lecanemab and Donanemab: Scales, Immunoreactivity, and Changes in Amyloid-β42}}, journal = {Journal of Alzheimer's disease : JAD}, year = {2024}, doi = {10.3233/jad-240171}, pmid = {38701151}, url = {https://doi.org/10.3233/jad-240171} } @article{rezai2024-38169490, author = {Rezai, A. R. and D'Haese, P. F. and Finomore, V. and Carpenter, J. and Ranjan, M. and Wilhelmsen, K. and Mehta, R. I. and Wang, P. and others}, title = {{Ultrasound Blood-Brain Barrier Opening and Aducanumab in Alzheimer's Disease}}, journal = {The New England journal of medicine}, year = {2024}, doi = {10.1056/nejmoa2308719}, pmid = {38169490}, url = {https://doi.org/10.1056/nejmoa2308719} } @article{hardy2024-38165303, author = {Hardy, John and Schott, Jonathan M}, title = {{Identifying Genetic Risk for Amyloid-Related Imaging Abnormalities}}, journal = {Neurology}, year = {2024}, doi = {10.1212/wnl.0000000000208096}, pmid = {38165303}, url = {https://doi.org/10.1212/wnl.0000000000208096} } @article{kaur2024-38095822, author = {Kaur, Upinder and Reddy, Jaideep and Tiwari, Ashutosh and Chakrabarti, Sasanka and Chakrabarti, Sankha Shubhra}, title = {{Lecanemab: More Questions Than Answers!}}, journal = {Clinical drug investigation}, year = {2024}, doi = {10.1007/s40261-023-01331-1}, pmid = {38095822}, url = {https://doi.org/10.1007/s40261-023-01331-1} } @article{solopova2023-38086820, author = {Solopova, E. and Romero-Fernandez, W. and Harmsen, H. and Ventura-Antunes, L. and Wang, E. and Shostak, A. and Maldonado, J. and Donahue, M. J. and others}, title = {{Fatal iatrogenic cerebral β-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer's disease}}, journal = {Nature communications}, year = {2023}, doi = {10.1038/s41467-023-43933-5}, pmid = {38086820}, url = {https://doi.org/10.1038/s41467-023-43933-5} } @article{mintun2023-3d9d0576, author = {Mintun, Mark A. and Ritchie, Craig William and Solomon, Paul R. and Sims, John Randall and Salloway, Stephen and Hansson, Oskar and Apostolova, Liana G. and Zimmer, Jennifer A. and others}, title = {{Donanemab in Early Symptomatic Alzheimer’s Disease: Efficacy and Safety in TRAILBLAZER‐ALZ 2, a Phase 3 Randomized Clinical Trial}}, journal = {Alzheimer s \& Dementia}, year = {2023}, doi = {10.1002/alz.082733}, url = {https://doi.org/10.1002/alz.082733} } @article{wu2023-38017568, author = {Wu, W. and Ji, Y. and Wang, Z. and Wu, X. and Li, J. and Gu, F. and Chen, Z.}, title = {{The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials}}, journal = {European journal of medical research}, year = {2023}, doi = {10.1186/s40001-023-01512-w}, pmid = {38017568}, url = {https://doi.org/10.1186/s40001-023-01512-w} } @article{urbach2024-37995736, author = {Urbach, H. and Linn, J. and Hattingen, E. and Fiebach, J.}, title = {{Imaging of Amyloid-Related Imaging Abnormalities (ARIA)}}, journal = {RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin}, year = {2024}, doi = {10.1055/a-2185-8472}, pmid = {37995736}, url = {https://doi.org/10.1055/a-2185-8472} } @article{dantas2024-37978096, author = {Dantas, J. M. and Mutarelli, A. and Navalha, D. D. P. and Dagostin, C. S. and Romeiro, P. H. C. L. and Felix, N. and Nogueira, A. and Batista, S. and others}, title = {{Efficacy of anti-amyloid-ß monoclonal antibody therapy in early Alzheimer's disease: a systematic review and meta-analysis}}, journal = {Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology}, year = {2024}, doi = {10.1007/s10072-023-07194-w}, pmid = {37978096}, url = {https://doi.org/10.1007/s10072-023-07194-w} } @article{cummings2024-37955845, author = {Cummings, J. and Osse, A. M. L. and Cammann, D. and Powell, J. and Chen, J.}, title = {{Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer's Disease}}, journal = {BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy}, year = {2024}, doi = {10.1007/s40259-023-00633-2}, pmid = {37955845}, url = {https://doi.org/10.1007/s40259-023-00633-2} } @article{kieu2023-38487381, author = {Kieu, Chinh and Look, Kevin A}, title = {{Cost-Effectiveness of a Hypothetical Gene Therapy for Alzheimer's Disease: A Markov Simulation Analysis}}, journal = {Innovations in pharmacy}, year = {2023}, doi = {10.24926/iip.v14i3.5500}, pmid = {38487381}, url = {https://doi.org/10.24926/iip.v14i3.5500} } @article{sin2023-37959255, author = {Sin, M. K. and Zamrini, E. and Ahmed, A. and Nho, K. and Hajjar, I.}, title = {{Anti-Amyloid Therapy, AD, and ARIA: Untangling the Role of CAA}}, journal = {Journal of clinical medicine}, year = {2023}, doi = {10.3390/jcm12216792}, pmid = {37959255}, url = {https://doi.org/10.3390/jcm12216792} } @article{lu2023-37936917, author = {Lu, O. and Kouser, T. and Skylar-Scott, I. A.}, title = {{Alzheimer's disease and epilepsy: shared neuropathology guides current and future treatment strategies}}, journal = {Frontiers in neurology}, year = {2023}, doi = {10.3389/fneur.2023.1241339}, pmid = {37936917}, url = {https://doi.org/10.3389/fneur.2023.1241339} } @article{boxer2023-37848035, author = {Boxer, A. L. and Sperling, R.}, title = {{Accelerating Alzheimer's therapeutic development: The past and future of clinical trials}}, journal = {Cell}, year = {2023}, doi = {10.1016/j.cell.2023.09.023}, pmid = {37848035}, url = {https://doi.org/10.1016/j.cell.2023.09.023} } @article{varadharajan2023-38059250, author = {Varadharajan, Ashvin and Davis, Aarjith Damian and Ghosh, Aishwarya and Jagtap, Tejaswini and Xavier, Anjo and Menon, Anjana Jayakumar and Roy, Dwaiti and Gandhi, Sandhya and others}, title = {{Guidelines for pharmacotherapy in Alzheimer's disease - A primer on FDA-approved drugs}}, journal = {Journal of neurosciences in rural practice}, year = {2023}, doi = {10.25259/jnrp_356_2023}, pmid = {38059250}, url = {https://doi.org/10.25259/jnrp_356_2023} } @article{kurkinen2023-37831471, author = {Kurkinen, Markku}, title = {{Donanemab: Not two without a third}}, journal = {Advances in clinical and experimental medicine : official organ Wroclaw Medical University}, year = {2023}, doi = {10.17219/acem/172673}, pmid = {37831471}, url = {https://doi.org/10.17219/acem/172673} } @article{kepp2023-37183523, author = {Kepp, K. P. and Robakis, N. K. and Høilund-Carlsen, P. F. and Sensi, S. L. and Vissel, B.}, title = {{The amyloid cascade hypothesis: an updated critical review}}, journal = {Brain : a journal of neurology}, year = {2023}, doi = {10.1093/brain/awad159}, pmid = {37183523}, url = {https://doi.org/10.1093/brain/awad159} } @article{bracoud2023-38026755, author = {Bracoud, L. and Klein, G. and Lyons, M. and Scelsi, M. A. and Wojtowicz, J. and Bullain, S. and Purcell, D. and Fiebach, J. B. and others}, title = {{Validation of 3- and 5-point severity scales to assess ARIA-E}}, journal = {Alzheimer's \& dementia (Amsterdam, Netherlands)}, year = {2023}, doi = {10.1002/dad2.12503}, pmid = {38026755}, url = {https://doi.org/10.1002/dad2.12503} } @article{chowdhury2023-39726673, author = {Chowdhury, Selia}, title = {{Monoclonal Antibody Treatments for Alzheimer's Disease: Aducanumab and Lecanemab}}, journal = {Discoveries (Craiova, Romania)}, year = {2023}, doi = {10.15190/d.2023.12}, pmid = {39726673}, url = {https://doi.org/10.15190/d.2023.12} } @article{fedele2023-37833948, author = {Fedele, Ernesto}, title = {{Anti-Amyloid Therapies for Alzheimer's Disease and the Amyloid Cascade Hypothesis}}, journal = {International journal of molecular sciences}, year = {2023}, doi = {10.3390/ijms241914499}, pmid = {37833948}, url = {https://doi.org/10.3390/ijms241914499} } @article{jucker2023-37729908, author = {Jucker, Mathias and Walker, Lary C}, title = {{Alzheimer's disease: From immunotherapy to immunoprevention}}, journal = {Cell}, year = {2023}, doi = {10.1016/j.cell.2023.08.021}, pmid = {37729908}, url = {https://doi.org/10.1016/j.cell.2023.08.021} } @article{zhang2023-37682322, author = {Zhang, Jinwei}, title = {{Commentaries: Lecanemab: pioneering the way as the first approved drug for Alzheimer's disease treatment}}, journal = {Inflammation research : official journal of the European Histamine Research Society ... [et al.]}, year = {2023}, doi = {10.1007/s00011-023-01788-y}, pmid = {37682322}, url = {https://doi.org/10.1007/s00011-023-01788-y} } @article{gonzales2023-37679434, author = {Gonzales, M. M. and Garbarino, V. R. and Kautz, T. F. and Palavicini, J. P. and Lopez-Cruzan, M. and Dehkordi, S. K. and Mathews, J. J. and Zare, H. and others}, title = {{Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial}}, journal = {Nature medicine}, year = {2023}, doi = {10.1038/s41591-023-02543-w}, pmid = {37679434}, url = {https://doi.org/10.1038/s41591-023-02543-w} } @article{kurkinen2023-37676096, author = {Kurkinen, Markku}, title = {{Lecanemab (Leqembi) is not the right drug for patients with Alzheimer's disease}}, journal = {Advances in clinical and experimental medicine : official organ Wroclaw Medical University}, year = {2023}, doi = {10.17219/acem/171379}, pmid = {37676096}, url = {https://doi.org/10.17219/acem/171379} } @article{ramanan2023-37495380, author = {Ramanan, V. K. and Armstrong, M. J. and Choudhury, P. and Coerver, K. A. and Hamilton, R. H. and Klein, B. C. and Wolk, D. A. and Wessels, SR. and others}, title = {{Antiamyloid Monoclonal Antibody Therapy for Alzheimer Disease: Emerging Issues in Neurology}}, journal = {Neurology}, year = {2023}, doi = {10.1212/wnl.0000000000207757}, pmid = {37495380}, url = {https://doi.org/10.1212/wnl.0000000000207757} } @article{yadollahikhales2023-37490245, author = {Yadollahikhales, G. and Rojas, J. C.}, title = {{Anti-Amyloid Immunotherapies for Alzheimer's Disease: A 2023 Clinical Update}}, journal = {Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics}, year = {2023}, doi = {10.1007/s13311-023-01405-0}, pmid = {37490245}, url = {https://doi.org/10.1007/s13311-023-01405-0} } @article{sperling2023-37458272, author = {Sperling, R. A. and Donohue, M. C. and Raman, R. and Rafii, M. S. and Johnson, K. and Masters, C. L. and van Dyck, C. H. and Iwatsubo, T. and others}, title = {{Trial of Solanezumab in Preclinical Alzheimer's Disease}}, journal = {The New England journal of medicine}, year = {2023}, doi = {10.1056/nejmoa2305032}, pmid = {37458272}, url = {https://doi.org/10.1056/nejmoa2305032} } @article{jeremic2023-37423541, author = {Jeremic, D. and Navarro-López, J. D. and Jiménez-Díaz, L.}, title = {{Efficacy and safety of anti-amyloid-β monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis}}, journal = {Ageing research reviews}, year = {2023}, doi = {10.1016/j.arr.2023.102012}, pmid = {37423541}, url = {https://doi.org/10.1016/j.arr.2023.102012} } @article{hoilundcarlsen2023-37414156, author = {Høilund-Carlsen, Poul F and Revheim, Mona-Elisabeth and Costa, Tommaso and Alavi, Abass and Kepp, Kasper P and Sensi, Stefano L and Perry, George and Robakis, Nikolaos K and others}, title = {{Passive Alzheimer's immunotherapy: A promising or uncertain option?}}, journal = {Ageing research reviews}, year = {2023}, doi = {10.1016/j.arr.2023.101996}, pmid = {37414156}, url = {https://doi.org/10.1016/j.arr.2023.101996} } @article{salemme2023-37975226, author = {Salemme, S. and Ancidoni, A. and Locuratolo, N. and Piscopo, P. and Lacorte, E. and Canevelli, M. and Vanacore, N.}, title = {{Advances in amyloid-targeting monoclonal antibodies for Alzheimer's disease: clinical and public health issues}}, journal = {Expert review of neurotherapeutics}, year = {2023}, doi = {10.1080/14737175.2023.2284305}, pmid = {37975226}, url = {https://doi.org/10.1080/14737175.2023.2284305} } @article{salloway2023-7521651f, author = {Salloway, Stephen and Lee, Elly and Papka, Michelle and Pain, Andrew and Oru, Ena and Ferguson, Margaret B. and Wang, Hong and Case, Michael G. and others}, title = {{TRAILBLAZER-ALZ 4: Topline Study Results Directly Comparing Donanemab to Aducanumab on Amyloid Lowering in Early, Symptomatic Alzheimer's Disease}}, journal = {BJPsych Open}, year = {2023}, doi = {10.1192/bjo.2023.227}, url = {https://doi.org/10.1192/bjo.2023.227} } @article{gueorguieva2023-37388759, author = {Gueorguieva, Ivelina and Willis, Brian A and Chua, Laiyi and Chow, Kay and Ernest, C Steven and Wang, Jian and Shcherbinin, Sergey and Sims, John R and others}, title = {{Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease}}, journal = {Alzheimer's \& dementia (New York, N. Y.)}, year = {2023}, doi = {10.1002/trc2.12404}, pmid = {37388759}, url = {https://doi.org/10.1002/trc2.12404} } @article{filippi2023-37382144, author = {Filippi, M. and Cecchetti, G. and Agosta, F.}, title = {{MRI in the new era of antiamyloid mAbs for the treatment of Alzheimer's disease}}, journal = {Current opinion in neurology}, year = {2023}, doi = {10.1097/wco.0000000000001177}, pmid = {37382144}, url = {https://doi.org/10.1097/wco.0000000000001177} } @article{alshamrani2023-37366656, author = {Alshamrani, Meshal}, title = {{Recent Trends in Active and Passive Immunotherapies of Alzheimer's Disease}}, journal = {Antibodies (Basel, Switzerland)}, year = {2023}, doi = {10.3390/antib12020041}, pmid = {37366656}, url = {https://doi.org/10.3390/antib12020041} } @article{knopman2023-37295957, author = {Knopman, D. S. and Hershey, L.}, title = {{Implications of the Approval of Lecanemab for Alzheimer Disease Patient Care: Incremental Step or Paradigm Shift?}}, journal = {Neurology}, year = {2023}, doi = {10.1212/wnl.0000000000207438}, pmid = {37295957}, url = {https://doi.org/10.1212/wnl.0000000000207438} } @article{jonsson2023-37251789, author = {Jönsson, Linus and Wimo, Anders and Handels, Ron and Johansson, Gunilla and Boada, Mercè and Engelborghs, Sebastiaan and Frölich, Lutz and Jessen, Frank and others}, title = {{The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint}}, journal = {The Lancet regional health. Europe}, year = {2023}, doi = {10.1016/j.lanepe.2023.100657}, pmid = {37251789}, url = {https://doi.org/10.1016/j.lanepe.2023.100657} } @article{qiao2023-37213538, author = {Qiao, Y. and Chi, Y. and Zhang, Q. and Ma, Y.}, title = {{Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials}}, journal = {Frontiers in aging neuroscience}, year = {2023}, doi = {10.3389/fnagi.2023.1169499}, pmid = {37213538}, url = {https://doi.org/10.3389/fnagi.2023.1169499} } @article{hardy2023-36797987, author = {Hardy, John and Mummery, Catherine}, title = {{An anti-amyloid therapy works for Alzheimer's disease: why has it taken so long and what is next?}}, journal = {Brain : a journal of neurology}, year = {2023}, doi = {10.1093/brain/awad049}, pmid = {36797987}, url = {https://doi.org/10.1093/brain/awad049} } @article{cummings2023-37060386, author = {Cummings, J.}, title = {{Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics}}, journal = {Drugs}, year = {2023}, doi = {10.1007/s40265-023-01858-9}, pmid = {37060386}, url = {https://doi.org/10.1007/s40265-023-01858-9} } @article{dranitsaris2023-36964606, author = {Dranitsaris, G. and Zhang, Q. and Mu, L. and Weyrer, C. and Drysdale, E. and Neumann, P. and Atri, A. and Monfared, A. A. T.}, title = {{Therapeutic preference for Alzheimer's disease treatments: a discrete choice experiment with caregivers and neurologists}}, journal = {Alzheimer's research \& therapy}, year = {2023}, doi = {10.1186/s13195-023-01207-8}, pmid = {36964606}, url = {https://doi.org/10.1186/s13195-023-01207-8} } @article{holdridge2023-36946603, author = {Holdridge, Karen C and Yaari, Roy and Hoban, Deirdre B and Andersen, Scott and Sims, John R}, title = {{Targeting amyloid β in Alzheimer's disease: Meta-analysis of low-dose solanezumab in Alzheimer's disease with mild dementia studies}}, journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association}, year = {2023}, doi = {10.1002/alz.13031}, pmid = {36946603}, url = {https://doi.org/10.1002/alz.13031} } @article{brodtmann2023-36934371, author = {Brodtmann, Amy G. and Darby, David and Oboudiyat, Carly and Mahoney, Colin and Le Heron, Campbell J. and Panegyres, Peter K. and Brew, Bruce J.}, title = {{Assessing preparedness for Alzheimer disease‐modifying therapies in Australasian health care systems}}, journal = {The Medical Journal of Australia}, year = {2023}, doi = {10.5694/mja2.51880}, pmid = {36934371}, url = {https://doi.org/10.5694/mja2.51880} } @article{gueorguieva2023-36805552, author = {Gueorguieva, I. and Willis, B. A. and Chua, L. and Chow, K. and Ernest, C. S. and Shcherbinin, S. and Ardayfio, P. and Mullins, G. R. and others}, title = {{Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease}}, journal = {Clinical pharmacology and therapeutics}, year = {2023}, doi = {10.1002/cpt.2875}, pmid = {36805552}, url = {https://doi.org/10.1002/cpt.2875} } @article{perneczky2023-36655336, author = {Perneczky, R. and Jessen, F. and Grimmer, T. and Levin, J. and Flöel, A. and Peters, O. and Froelich, L.}, title = {{Anti-amyloid antibody therapies in Alzheimer's disease}}, journal = {Brain : a journal of neurology}, year = {2023}, doi = {10.1093/brain/awad005}, pmid = {36655336}, url = {https://doi.org/10.1093/brain/awad005} } @article{hoy2023-36856953, author = {Hoy, S. M.}, title = {{Lecanemab: First Approval}}, journal = {Drugs}, year = {2023}, doi = {10.1007/s40265-023-01851-2}, pmid = {36856953}, url = {https://doi.org/10.1007/s40265-023-01851-2} } @article{rahman2023-36775284, author = {Rahman, Afroza and Hossen, Md Anwar and Chowdhury, Mirza Farhana Iqbal and Bari, Sadia and Tamanna, Nuzhat and Sultana, Syeda Salima and Haque, Sharar Naiarin and Masud, Abdullah Al and others}, title = {{Aducanumab for the treatment of Alzheimer's disease: a systematic review}}, journal = {Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society}, year = {2023}, doi = {10.1111/psyg.12944}, pmid = {36775284}, url = {https://doi.org/10.1111/psyg.12944} } @article{geerts2023-36632701, author = {Geerts, H. and Walker, M. and Rose, R. and Bergeler, S. and van der Graaf, P. H. and Schuck, E. and Koyama, A. and Yasuda, S. and others}, title = {{A combined physiologically-based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's disease}}, journal = {CPT: pharmacometrics \& systems pharmacology}, year = {2023}, doi = {10.1002/psp4.12912}, pmid = {36632701}, url = {https://doi.org/10.1002/psp4.12912} } @article{siemers2023-36641606, author = {Siemers, E. and Hitchcock, J. and Sundell, K. and Dean, R. and Jerecic, J. and Cline, E. and Iverson, K. and Moore, J. and others}, title = {{ACU193, a Monoclonal Antibody that Selectively Binds Soluble Aß Oligomers: Development Rationale, Phase 1 Trial Design, and Clinical Development Plan}}, journal = {The journal of prevention of Alzheimer's disease}, year = {2023}, doi = {10.14283/jpad.2022.93}, pmid = {36641606}, url = {https://doi.org/10.14283/jpad.2022.93} } @article{honig2023-36949897, author = {Honig, L. S. and Barakos, J. and Dhadda, S. and Kanekiyo, M. and Reyderman, L. and Irizarry, M. and Kramer, L. D. and Swanson, C. J. and others}, title = {{ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease}}, journal = {Alzheimer's \& dementia (New York, N. Y.)}, year = {2023}, doi = {10.1002/trc2.12377}, pmid = {36949897}, url = {https://doi.org/10.1002/trc2.12377} } @article{grimm2023-37823690, author = {Grimm, H. P. and Schumacher, V. and Schäfer, M. and Imhof-Jung, S. and Freskgård, P. O. and Brady, K. and Hofmann, C. and Rüger, P. and others}, title = {{Delivery of the Brainshuttle™ amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans}}, journal = {mAbs}, year = {2023}, doi = {10.1080/19420862.2023.2261509}, pmid = {37823690}, url = {https://doi.org/10.1080/19420862.2023.2261509} } @article{howe2023-37874098, author = {Howe, M. D. and Britton, K. J. and Joyce, H. E. and Pappas, G. J. and Faust, M. A. and Dawson, B. C. and Riddle, M. C. and Salloway, S. P.}, title = {{Initial Experiences with Amyloid-Related Imaging Abnormalities in Patients Receiving Aducanumab Following Accelerated Approval}}, journal = {The journal of prevention of Alzheimer's disease}, year = {2023}, doi = {10.14283/jpad.2023.96}, pmid = {37874098}, url = {https://doi.org/10.14283/jpad.2023.96} } @article{mallinckrodt2023-36946443, author = {Mallinckrodt, C and Tian, Y and Aisen, P S and Barkhof, F and Cohen, S and Dent, G and Hansson, O and Harrison, K and others}, title = {{Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab}}, journal = {The journal of prevention of Alzheimer's disease}, year = {2023}, doi = {10.14283/jpad.2023.6}, pmid = {36946443}, url = {https://doi.org/10.14283/jpad.2023.6} } @article{cohen2023-37874099, author = {Cohen, S and van Dyck, C H and Gee, M and Doherty, T and Kanekiyo, M and Dhadda, S and Li, D and Hersch, S and others}, title = {{Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer's Disease}}, journal = {The journal of prevention of Alzheimer's disease}, year = {2023}, doi = {10.14283/jpad.2023.123}, pmid = {37874099}, url = {https://doi.org/10.14283/jpad.2023.123} } @article{castellani2023-37125554, author = {Castellani, Rudolph J and Shanes, Elisheva D and McCord, Matthew and Reish, Nicholas J and Flanagan, Margaret E and Mesulam, M-Marsel and Jamshidi, Pouya}, title = {{Neuropathology of Anti-Amyloid-β Immunotherapy: A Case Report}}, journal = {Journal of Alzheimer's disease : JAD}, year = {2023}, doi = {10.3233/jad-221305}, pmid = {37125554}, url = {https://doi.org/10.3233/jad-221305} } @article{chowdhury2023-37902139, author = {Chowdhury, Selia and Chowdhury, Nurjahan Shipa}, title = {{Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review}}, journal = {International journal of immunopathology and pharmacology}, year = {2023}, doi = {10.1177/03946320231209839}, pmid = {37902139}, url = {https://doi.org/10.1177/03946320231209839} } @article{kepp2023-37334596, author = {Kepp, Kasper P and Sensi, Stefano L and Johnsen, Kasper B and Barrio, Jorge R and Høilund-Carlsen, Poul F and Neve, Rachael L and Alavi, Abass and Herrup, Karl and others}, title = {{The Anti-Amyloid Monoclonal Antibody Lecanemab: 16 Cautionary Notes}}, journal = {Journal of Alzheimer's disease : JAD}, year = {2023}, doi = {10.3233/jad-230099}, pmid = {37334596}, url = {https://doi.org/10.3233/jad-230099} } @article{gauthier2023-37357267, author = {Gauthier, S and Ismail, Z and Goodarzi, Z and Ng, K P and Rosa-Neto, P}, title = {{Viewpoint: Clinicians' Perspectives on How Disease Modifying Drugs for Alzheimer's Disease Impact Specialty Care}}, journal = {The journal of prevention of Alzheimer's disease}, year = {2023}, doi = {10.14283/jpad.2023.72}, pmid = {37357267}, url = {https://doi.org/10.14283/jpad.2023.72} } @article{rashad2022-36611492, author = {Rashad, A. and Rasool, A. and Shaheryar, M. and Sarfraz, A. and Sarfraz, Z. and Robles-Velasco, K. and Cherrez-Ojeda, I.}, title = {{Donanemab for Alzheimer's Disease: A Systematic Review of Clinical Trials}}, journal = {Healthcare (Basel, Switzerland)}, year = {2022}, doi = {10.3390/healthcare11010032}, pmid = {36611492}, url = {https://doi.org/10.3390/healthcare11010032} } @article{mcdade2022-36544184, author = {McDade, E. and Cummings, J. L. and Dhadda, S. and Swanson, C. J. and Reyderman, L. and Kanekiyo, M. and Koyama, A. and Irizarry, M. and others}, title = {{Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study}}, journal = {Alzheimer's research \& therapy}, year = {2022}, doi = {10.1186/s13195-022-01124-2}, pmid = {36544184}, url = {https://doi.org/10.1186/s13195-022-01124-2} } @article{bateman2022-36447240, author = {Bateman, Randall J and Cummings, Jeffrey and Schobel, Scott and Salloway, Stephen and Vellas, Bruno and Boada, Mercè and Black, Sandra E and Blennow, Kaj and others}, title = {{Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer's disease}}, journal = {Alzheimer's research \& therapy}, year = {2022}, doi = {10.1186/s13195-022-01110-8}, pmid = {36447240}, url = {https://doi.org/10.1186/s13195-022-01110-8} } @article{soderberg2023-36253511, author = {Söderberg, L. and Johannesson, M. and Nygren, P. and Laudon, H. and Eriksson, F. and Osswald, G. and Möller, C. and Lannfelt, L.}, title = {{Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease}}, journal = {Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics}, year = {2023}, doi = {10.1007/s13311-022-01308-6}, pmid = {36253511}, url = {https://doi.org/10.1007/s13311-022-01308-6} } @article{villain2022-36184326, author = {Villain, N. and Planche, V. and Levy, R.}, title = {{High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects}}, journal = {Revue neurologique}, year = {2022}, doi = {10.1016/j.neurol.2022.06.012}, pmid = {36184326}, url = {https://doi.org/10.1016/j.neurol.2022.06.012} } @article{hao2022-36054214, author = {Hao, Wenrui and Lenhart, Suzanne and Petrella, Jeffrey R}, title = {{Optimal anti-amyloid-beta therapy for Alzheimer's disease via a personalized mathematical model}}, journal = {PLoS computational biology}, year = {2022}, doi = {10.1371/journal.pcbi.1010481}, pmid = {36054214}, url = {https://doi.org/10.1371/journal.pcbi.1010481} } @article{yuksel2022-35879846, author = {Yuksel, J. M. and Noviasky, J. and Britton, S.}, title = {{Aducanumab for Alzheimer's Disease: Summarized Data From EMERGE, ENGAGE, and PRIME Studies}}, journal = {The Senior care pharmacist}, year = {2022}, doi = {10.4140/tcp.n.2022.329}, pmid = {35879846}, url = {https://doi.org/10.4140/tcp.n.2022.329} } @article{haass2022-35862308, author = {Haass, C. and Selkoe, D.}, title = {{If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline?}}, journal = {PLoS biology}, year = {2022}, doi = {10.1371/journal.pbio.3001694}, pmid = {35862308}, url = {https://doi.org/10.1371/journal.pbio.3001694} } @article{aldea2022-35676943, author = {Aldea, R. and Grimm, H. P. and Gieschke, R. and Hofmann, C. and Lott, D. and Bullain, S. and Delmar, P. and Klein, G. and others}, title = {{In silico exploration of amyloid-related imaging abnormalities in the gantenerumab open-label extension trials using a semi-mechanistic model}}, journal = {Alzheimer's \& dementia (New York, N. Y.)}, year = {2022}, doi = {10.1002/trc2.12306}, pmid = {35676943}, url = {https://doi.org/10.1002/trc2.12306} } @article{vaz2022-35611326, author = {Vaz, M. and Silva, V. and Monteiro, C. and Silvestre, S.}, title = {{Role of Aducanumab in the Treatment of Alzheimer's Disease: Challenges and Opportunities}}, journal = {Clinical interventions in aging}, year = {2022}, doi = {10.2147/cia.s325026}, pmid = {35611326}, url = {https://doi.org/10.2147/cia.s325026} } @article{cummings2022-35516416, author = {Cummings, J. and Lee, G. and Nahed, P. and Kambar, M. E. Z. N. and Zhong, K. and Fonseca, J. and Taghva, K.}, title = {{Alzheimer's disease drug development pipeline: 2022}}, journal = {Alzheimer's \& dementia (New York, N. Y.)}, year = {2022}, doi = {10.1002/trc2.12295}, pmid = {35516416}, url = {https://doi.org/10.1002/trc2.12295} } @article{villain2022-35489824, author = {Villain, N}, title = {{Therapeutic news in Alzheimer's disease: Soon a disease-modifying therapy?}}, journal = {Revue neurologique}, year = {2022}, doi = {10.1016/j.neurol.2022.02.456}, pmid = {35489824}, url = {https://doi.org/10.1016/j.neurol.2022.02.456} } @article{shi2022-35493943, author = {Shi, M. and Chu, F. and Zhu, F. and Zhu, J.}, title = {{Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer's Disease: A Focus on Aducanumab and Lecanemab}}, journal = {Frontiers in aging neuroscience}, year = {2022}, doi = {10.3389/fnagi.2022.870517}, pmid = {35493943}, url = {https://doi.org/10.3389/fnagi.2022.870517} } @article{aisen2022-35379951, author = {Aisen, P. S. and Jimenez-Maggiora, G. A. and Rafii, M. S. and Walter, S. and Raman, R.}, title = {{Early-stage Alzheimer disease: getting trial-ready}}, journal = {Nature reviews. Neurology}, year = {2022}, doi = {10.1038/s41582-022-00645-6}, pmid = {35379951}, url = {https://doi.org/10.1038/s41582-022-00645-6} } @article{wang2022-35320578, author = {Wang, D. and Kowalewski, E. K. and Koch, G.}, title = {{Application of Meta-analysis to Evaluate Relationships Among ARIA-E Rate, Amyloid Reduction Rate, and Clinical Cognitive Response in Amyloid Therapeutic Clinical Trials for Early Alzheimer's Disease}}, journal = {Therapeutic innovation \& regulatory science}, year = {2022}, doi = {10.1007/s43441-022-00390-4}, pmid = {35320578}, url = {https://doi.org/10.1007/s43441-022-00390-4} } @article{retout2022-35100444, author = {Retout, S. and Gieschke, R. and Serafin, D. and Weber, C. and Frey, N. and Hofmann, C.}, title = {{Disease Modeling and Model-Based Meta-Analyses to Define a New Direction for a Phase III Program of Gantenerumab in Alzheimer's Disease}}, journal = {Clinical pharmacology and therapeutics}, year = {2022}, doi = {10.1002/cpt.2535}, pmid = {35100444}, url = {https://doi.org/10.1002/cpt.2535} } @article{behl2022-35231697, author = {Behl, T. and Kaur, I. and Sehgal, A. and Singh, S. and Sharma, N. and Makeen, H. A. and Albratty, M. and Alhazmi, H. A. and others}, title = {{"Aducanumab" making a comeback in Alzheimer's disease: An old wine in a new bottle}}, journal = {Biomedicine \& pharmacotherapy = Biomedecine \& pharmacotherapie}, year = {2022}, doi = {10.1016/j.biopha.2022.112746}, pmid = {35231697}, url = {https://doi.org/10.1016/j.biopha.2022.112746} } @article{lam2022-35190446, author = {Lam, Virginie and Clarnette, Roger and Francis, Roslyn and Bynevelt, Michael and Watts, Gerald and Flicker, Leon and Orr, Carolyn F and Loh, Poh and others}, title = {{Efficacy of probucol on cognitive function in Alzheimer's disease: study protocol for a double-blind, placebo-controlled, randomised phase II trial (PIA study)}}, journal = {BMJ open}, year = {2022}, doi = {10.1136/bmjopen-2021-058826}, pmid = {35190446}, url = {https://doi.org/10.1136/bmjopen-2021-058826} } @article{haddad2022-35928986, author = {Haddad, Hannah W and Malone, Garett W and Comardelle, Nicholas J and Degueure, Arielle E and Kaye, Adam M and Kaye, Alan D}, title = {{Aducanumab, a Novel Anti-Amyloid Monoclonal Antibody, for the Treatment of Alzheimer's Disease: A Comprehensive Review}}, journal = {Health psychology research}, year = {2022}, doi = {10.52965/001c.31925}, pmid = {35928986}, url = {https://doi.org/10.52965/001c.31925} } @article{cummings2022-35542993, author = {Cummings, J. and Rabinovici, G. D. and Atri, A. and Aisen, P. and Apostolova, L. G. and Hendrix, S. and Sabbagh, M. and Selkoe, D. and others}, title = {{Aducanumab: Appropriate Use Recommendations Update}}, journal = {The journal of prevention of Alzheimer's disease}, year = {2022}, doi = {10.14283/jpad.2022.34}, pmid = {35542993}, url = {https://doi.org/10.14283/jpad.2022.34} } @article{kim2022-35342092, author = {Kim, C. K. and Lee, Y. R. and Ong, L. and Gold, M. and Kalali, A. and Sarkar, J.}, title = {{Alzheimer's Disease: Key Insights from Two Decades of Clinical Trial Failures}}, journal = {Journal of Alzheimer's disease : JAD}, year = {2022}, doi = {10.3233/jad-215699}, pmid = {35342092}, url = {https://doi.org/10.3233/jad-215699} } @article{barakos2022-35542992, author = {Barakos, J. and Purcell, D. and Suhy, J. and Chalkias, S. and Burkett, P. and Marsica Grassi, C. and Castrillo-Viguera, C. and Rubino, I. and others}, title = {{Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy}}, journal = {The journal of prevention of Alzheimer's disease}, year = {2022}, doi = {10.14283/jpad.2022.21}, pmid = {35542992}, url = {https://doi.org/10.14283/jpad.2022.21} } @article{golde2022-35229269, author = {Golde, T. E.}, title = {{Disease-Modifying Therapies for Alzheimer's Disease: More Questions than Answers}}, journal = {Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics}, year = {2022}, doi = {10.1007/s13311-022-01201-2}, pmid = {35229269}, url = {https://doi.org/10.1007/s13311-022-01201-2} } @article{gettman2022-c153db12, author = {Gettman, Lana}, title = {{New Drug Update: Dostarlimab, Loncastuximab Tesirine, and Aducanumab}}, journal = {The Senior Care Pharmacist}, year = {2022}, doi = {10.4140/tcp.n.2022.9}, url = {https://doi.org/10.4140/tcp.n.2022.9} } @article{lacorte2022-35275549, author = {Lacorte, E. and Ancidoni, A. and Zaccaria, V. and Remoli, G. and Tariciotti, L. and Bellomo, G. and Sciancalepore, F. and Corbo, M. and others}, title = {{Safety and Efficacy of Monoclonal Antibodies for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Published and Unpublished Clinical Trials}}, journal = {Journal of Alzheimer's disease : JAD}, year = {2022}, doi = {10.3233/jad-220046}, pmid = {35275549}, url = {https://doi.org/10.3233/jad-220046} } @article{chertkow2021-b7d8f16f, author = {Chertkow, Howard and Rockwood, Kenneth and Hogan, David B. and Phillips, Natalie and Montero-Odasso, Manuel and Amanullah, Shabbir and Black, Sandra and Bocti, Christian and others}, title = {{Consensus Statement Regarding the Application of Biogen to Health Canada for Approval of Aducanumab}}, journal = {Canadian Geriatrics Journal}, year = {2021}, doi = {10.5770/cgj.24.570}, url = {https://doi.org/10.5770/cgj.24.570} } @article{gunawardena2021-8f1e1182, author = {Gunawardena, Illangage P. C. and Retinasamy, Thaarvena and Shaikh, Mohd. Farooq}, title = {{Is Aducanumab for LMICs? Promises and Challenges}}, journal = {Brain Sciences}, year = {2021}, doi = {10.3390/brainsci11111547}, url = {https://doi.org/10.3390/brainsci11111547} } @article{kehoe2021-34687634, author = {Kehoe, Patrick Gavin and Turner, Nicholas and Howden, Beth and Jarutyte, Lina and Clegg, Shona Louise and Malone, Ian Brian and Barnes, Josephine and Nielsen, Casper and others}, title = {{Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial}}, journal = {The Lancet. Neurology}, year = {2021}, doi = {10.1016/s1474-4422(21)00263-5}, pmid = {34687634}, url = {https://doi.org/10.1016/s1474-4422(21)00263-5} } @article{synnott2021-34714106, author = {Synnott, Patricia G and Whittington, Melanie D and Lin, Grace A and Rind, David M and Pearson, Steven D}, title = {{The effectiveness and value of aducanumab for Alzheimer's disease}}, journal = {Journal of managed care \& specialty pharmacy}, year = {2021}, doi = {10.18553/jmcp.2021.27.11.1613}, pmid = {34714106}, url = {https://doi.org/10.18553/jmcp.2021.27.11.1613} } @article{muralidharan2021-098ca6fa, author = {Muralidharan, Kumar Kandadi and Tong, Xiao and Kowalski, Kenneth G. and Rajagovindan, Raj and Lin, Lin and Haberlain, Samantha Budd and Nestorov, Ivan}, title = {{Population pharmacokinetics and standard uptake value ratio of aducanumab, an amyloid plaque–removing agent, in patients with Alzheimer’s disease}}, journal = {CPT: Pharmacometrics \& Systems Pharmacology}, year = {2021}, doi = {10.1002/psp4.12728}, url = {https://doi.org/10.1002/psp4.12728} } @article{jeremic2021-34687956, author = {Jeremic, D. and Jiménez-Díaz, L. and Navarro-López, J. D.}, title = {{Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer's disease: a systematic review}}, journal = {Ageing research reviews}, year = {2021}, doi = {10.1016/j.arr.2021.101496}, pmid = {34687956}, url = {https://doi.org/10.1016/j.arr.2021.101496} } @article{mukhopadhyay2021-4e65c051, author = {Mukhopadhyay, Sanchari and Banerjee, Debanjan}, title = {{A Primer on the Evolution of Aducanumab: The First Antibody Approved for Treatment of Alzheimer’s Disease}}, journal = {Journal of Alzheimer's Disease}, year = {2021}, doi = {10.3233/jad-215065}, url = {https://doi.org/10.3233/jad-215065} } @article{tampi2021-34650610, author = {Tampi, R. R. and Forester, B. P. and Agronin, M.}, title = {{Aducanumab: evidence from clinical trial data and controversies}}, journal = {Drugs in context}, year = {2021}, doi = {10.7573/dic.2021-7-3}, pmid = {34650610}, url = {https://doi.org/10.7573/dic.2021-7-3} } @article{sanchezmontoya2021-27930c38, author = {Sánchez-Montoya, Eliana and Andresen, Max and Corrales, Raúl and Gallardo, Jorge and Noriega, Viviana and Weinstein-Oppenheimer, Caroline R.}, title = {{caso de aducanumab ¿Más esperanza que ciencia?}}, journal = {ARS MEDICA Revista de Ciencias Médicas}, year = {2021}, doi = {10.11565/arsmed.v46i3.1826}, url = {https://doi.org/10.11565/arsmed.v46i3.1826} } @article{kang2022-34378436, author = {Kang, Min Su and Shin, Monica and Ottoy, Julie and Aliaga, Arturo Aliaga and Mathotaarachchi, Sulantha and Quispialaya, Kely and Pascoal, Tharick A and Collins, D Louis and others}, title = {{Preclinical in vivo longitudinal assessment of KG207-M as a disease-modifying Alzheimer's disease therapeutic}}, journal = {Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism}, year = {2022}, doi = {10.1177/0271678x211035625}, pmid = {34378436}, url = {https://doi.org/10.1177/0271678x211035625} } @article{lalli2021-f2e71f9d, author = {Lalli, Giovanna and Schott, Jonathan M and Hardy, John and De Strooper, Bart}, title = {{Aducanumab: a new phase in therapeutic development for Alzheimer’s disease?}}, journal = {EMBO Molecular Medicine}, year = {2021}, doi = {10.15252/emmm.202114781}, url = {https://doi.org/10.15252/emmm.202114781} } @article{dhillon2021-34324167, author = {Dhillon, S.}, title = {{Aducanumab: First Approval}}, journal = {Drugs}, year = {2021}, doi = {10.1007/s40265-021-01569-z}, pmid = {34324167}, url = {https://doi.org/10.1007/s40265-021-01569-z} } @article{thomas2021-6ea281e6, author = {Thomas, Emily and Wasunna‐Smith, Brenda and Kuruvilla, Tarun}, title = {{Aducanumab and disease modifying treatments for Alzheimer's disease}}, journal = {Progress in Neurology and Psychiatry}, year = {2021}, doi = {10.1002/pnp.711}, url = {https://doi.org/10.1002/pnp.711} } @article{retinasamy2021-3dd6d026, author = {Retinasamy, Thaarvena and Shaikh, Mohd. Farooq}, title = {{Aducanumab for Alzheimer's disease: An update}}, journal = {Neuroscience Research Notes}, year = {2021}, doi = {10.31117/neuroscirn.v4i2.81}, url = {https://doi.org/10.31117/neuroscirn.v4i2.81} } @article{salloway2021-34155411, author = {Salloway, S. and Farlow, M. and McDade, E. and Clifford, D. B. and Wang, G. and Llibre-Guerra, J. J. and Hitchcock, J. M. and Mills, S. L. and others}, title = {{A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease}}, journal = {Nature medicine}, year = {2021}, doi = {10.1038/s41591-021-01369-8}, pmid = {34155411}, url = {https://doi.org/10.1038/s41591-021-01369-8} } @article{tolar2021-34198582, author = {Tolar, M. and Hey, J. and Power, A. and Abushakra, S.}, title = {{Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer's Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression}}, journal = {International journal of molecular sciences}, year = {2021}, doi = {10.3390/ijms22126355}, pmid = {34198582}, url = {https://doi.org/10.3390/ijms22126355} } @article{study2021-38d83515, title = {{Donanemab leads to less decline in early Alzheimer's disease}}, journal = {The Brown University Psychopharmacology Update}, year = {2021}, doi = {10.1002/pu.30739}, url = {https://doi.org/10.1002/pu.30739} } @article{cummings2021-34095440, author = {Cummings, J. and Lee, G. and Zhong, K. and Fonseca, J. and Taghva, K.}, title = {{Alzheimer's disease drug development pipeline: 2021}}, journal = {Alzheimer's \& dementia (New York, N. Y.)}, year = {2021}, doi = {10.1002/trc2.12179}, pmid = {34095440}, url = {https://doi.org/10.1002/trc2.12179} } @article{ancidoni2021-33952306, author = {Ancidoni, Antonio and Bacigalupo, Ilaria and Remoli, Giulia and Lacorte, Eleonora and Piscopo, Paola and Sarti, Giulia and Corbo, Massimo and Vanacore, Nicola and others}, title = {{Anticancer drugs repurposed for Alzheimer's disease: a systematic review}}, journal = {Alzheimer's research \& therapy}, year = {2021}, doi = {10.1186/s13195-021-00831-6}, pmid = {33952306}, url = {https://doi.org/10.1186/s13195-021-00831-6} } @article{madrasi2021-33938131, author = {Madrasi, Kumpal and Das, Raibatak and Mohmmadabdul, Hafiz and Lin, Lin and Hyman, Bradley T and Lauffenburger, Douglas A and Albers, Mark W and Rissman, Robert A and others}, title = {{Systematic in silico analysis of clinically tested drugs for reducing amyloid-beta plaque accumulation in Alzheimer's disease}}, journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association}, year = {2021}, doi = {10.1002/alz.12312}, pmid = {33938131}, url = {https://doi.org/10.1002/alz.12312} } @article{avgerinos2021-33831607, author = {Avgerinos, K. I. and Ferrucci, L. and Kapogiannis, D.}, title = {{Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease}}, journal = {Ageing research reviews}, year = {2021}, doi = {10.1016/j.arr.2021.101339}, pmid = {33831607}, url = {https://doi.org/10.1016/j.arr.2021.101339} } @article{friedman2021-33674360, author = {Friedman, Lauren G and McKeehan, Nicholas and Hara, Yuko and Cummings, Jeffrey L and Matthews, Dawn C and Zhu, Jian and Mohs, Richard C and Wang, Deli and others}, title = {{Value-Generating Exploratory Trials in Neurodegenerative Dementias}}, journal = {Neurology}, year = {2021}, doi = {10.1212/wnl.0000000000011774}, pmid = {33674360}, url = {https://doi.org/10.1212/wnl.0000000000011774} } @article{ackley2021-33632704, author = {Ackley, S. F. and Zimmerman, S. C. and Brenowitz, W. D. and Tchetgen Tchetgen, E. J. and Gold, A. L. and Manly, J. J. and Mayeda, E. R. and Filshtein, T. J. and others}, title = {{Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis}}, journal = {BMJ (Clinical research ed.)}, year = {2021}, doi = {10.1136/bmj.n156}, pmid = {33632704}, url = {https://doi.org/10.1136/bmj.n156} } @article{cummings2021-34585212, author = {Cummings, J. and Aisen, P. and Apostolova, L. G. and Atri, A. and Salloway, S. and Weiner, M.}, title = {{Aducanumab: Appropriate Use Recommendations}}, journal = {The journal of prevention of Alzheimer's disease}, year = {2021}, doi = {10.14283/jpad.2021.41}, pmid = {34585212}, url = {https://doi.org/10.14283/jpad.2021.41} } @article{lowe2021-3ffcda2a, author = {Lowe, Stephen Loucian and Willis, Brian A. and Hawdon, Anne and Natanegara, Fanni and Chua, Laiyi and Foster, Joanne and Shcherbinin, Sergey and Ardayfio, Paul and others}, title = {{Donanemab (LY3002813) dose‐escalation study in Alzheimer's disease}}, journal = {Alzheimer's \& Dementia: Translational Research \& Clinical Interventions}, year = {2021}, doi = {10.1002/trc2.12112}, url = {https://doi.org/10.1002/trc2.12112} } @article{lowe2021-34585215, author = {Lowe, S L and Evans, C Duggan and Shcherbinin, S and Cheng, Y-J and Willis, B A and Gueorguieva, I and Lo, A C and Fleisher, A S and others}, title = {{Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging}}, journal = {The journal of prevention of Alzheimer's disease}, year = {2021}, doi = {10.14283/jpad.2021.56}, pmid = {34585215}, url = {https://doi.org/10.14283/jpad.2021.56} } @article{imbimbo2021-33575481, author = {Imbimbo, Bruno P and Lucca, Ugo and Watling, Mark}, title = {{Can Anti-β-amyloid Monoclonal Antibodies Work in Autosomal Dominant Alzheimer Disease?}}, journal = {Neurology. Genetics}, year = {2021}, doi = {10.1212/nxg.0000000000000535}, pmid = {33575481}, url = {https://doi.org/10.1212/nxg.0000000000000535} } @article{munafo2020-33343293, author = {Munafò, Antonio and Burgaletto, Chiara and Di Benedetto, Giulia and Di Mauro, Marco and Di Mauro, Rosaria and Bernardini, Renato and Cantarella, Giuseppina}, title = {{Repositioning of Immunomodulators: A Ray of Hope for Alzheimer's Disease?}}, journal = {Frontiers in neuroscience}, year = {2020}, doi = {10.3389/fnins.2020.614643}, pmid = {33343293}, url = {https://doi.org/10.3389/fnins.2020.614643} } @article{knopman2021-33135381, author = {Knopman, D. S. and Jones, D. T. and Greicius, M. D.}, title = {{Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019}}, journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association}, year = {2021}, doi = {10.1002/alz.12213}, pmid = {33135381}, url = {https://doi.org/10.1002/alz.12213} } @article{sabbagh2020-33135288, author = {Sabbagh, Marwan Noel and Cummings, Jeffrey L.}, title = {{Open Peer Commentary to “Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE Trials as reported by Biogen December 2019”}}, journal = {Alzheimer s \& Dementia}, year = {2020}, doi = {10.1002/alz.12235}, pmid = {33135288}, url = {https://doi.org/10.1002/alz.12235} } @article{vandevrede2020-33072846, author = {VandeVrede, Lawren and Gibbs, Daniel M and Koestler, Mary and La Joie, Renaud and Ljubenkov, Peter A and Provost, Karine and Soleimani-Meigooni, David and Strom, Amelia and others}, title = {{Symptomatic amyloid-related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab}}, journal = {Alzheimer's \& dementia (Amsterdam, Netherlands)}, year = {2020}, doi = {10.1002/dad2.12101}, pmid = {33072846}, url = {https://doi.org/10.1002/dad2.12101} } @article{linse2020-32989305, author = {Linse, S. and Scheidt, T. and Bernfur, K. and Vendruscolo, M. and Dobson, C. M. and Cohen, S. I. A. and Sileikis, E. and Lundqvist, M. and others}, title = {{Kinetic fingerprints differentiate the mechanisms of action of anti-Aβ antibodies}}, journal = {Nature structural \& molecular biology}, year = {2020}, doi = {10.1038/s41594-020-0505-6}, pmid = {32989305}, url = {https://doi.org/10.1038/s41594-020-0505-6} } @article{bauzon2020-32807237, author = {Bauzon, Justin and Lee, Garam and Cummings, Jeffrey}, title = {{Repurposed agents in the Alzheimer's disease drug development pipeline}}, journal = {Alzheimer's research \& therapy}, year = {2020}, doi = {10.1186/s13195-020-00662-x}, pmid = {32807237}, url = {https://doi.org/10.1186/s13195-020-00662-x} } @article{cummings2020-32695874, author = {Cummings, J. and Lee, G. and Ritter, A. and Sabbagh, M. and Zhong, K.}, title = {{Alzheimer's disease drug development pipeline: 2020}}, journal = {Alzheimer's \& dementia (New York, N. Y.)}, year = {2020}, doi = {10.1002/trc2.12050}, pmid = {32695874}, url = {https://doi.org/10.1002/trc2.12050} } @article{mullane2020-32247851, author = {Mullane, K. and Williams, M.}, title = {{Alzheimer's disease beyond amyloid: Can the repetitive failures of amyloid-targeted therapeutics inform future approaches to dementia drug discovery?}}, journal = {Biochemical pharmacology}, year = {2020}, doi = {10.1016/j.bcp.2020.113945}, pmid = {32247851}, url = {https://doi.org/10.1016/j.bcp.2020.113945} } @article{tolar2020-31706733, author = {Tolar, M. and Abushakra, S. and Sabbagh, M.}, title = {{The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis}}, journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association}, year = {2020}, doi = {10.1016/j.jalz.2019.09.075}, pmid = {31706733}, url = {https://doi.org/10.1016/j.jalz.2019.09.075} } @article{ihara2020-32144994, author = {Ihara, Masafumi and Saito, Satoshi}, title = {{Drug Repositioning for Alzheimer's Disease: Finding Hidden Clues in Old Drugs}}, journal = {Journal of Alzheimer's disease : JAD}, year = {2020}, doi = {10.3233/jad-200049}, pmid = {32144994}, url = {https://doi.org/10.3233/jad-200049} } @article{guthrie2020-32568196, author = {Guthrie, H. and Honig, L. S. and Lin, H. and Sink, K. M. and Blondeau, K. and Quartino, A. and Dolton, M. and Carrasco-Triguero, M. and others}, title = {{Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer's Disease Treated with Escalating Doses for up to 133 Weeks}}, journal = {Journal of Alzheimer's disease : JAD}, year = {2020}, doi = {10.3233/jad-200134}, pmid = {32568196}, url = {https://doi.org/10.3233/jad-200134} } @article{aisen2020-32463066, author = {Aisen, P. S. and Cummings, J. and Doody, R. and Kramer, L. and Salloway, S. and Selkoe, D. J. and Sims, J. and Sperling, R. A. and others}, title = {{The Future of Anti-Amyloid Trials}}, journal = {The journal of prevention of Alzheimer's disease}, year = {2020}, doi = {10.14283/jpad.2020.24}, pmid = {32463066}, url = {https://doi.org/10.14283/jpad.2020.24} } @article{klein2019-31831056, author = {Klein, G. and Delmar, P. and Voyle, N. and Rehal, S. and Hofmann, C. and Abi-Saab, D. and Andjelkovic, M. and Ristic, S. and others}, title = {{Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis}}, journal = {Alzheimer's research \& therapy}, year = {2019}, doi = {10.1186/s13195-019-0559-z}, pmid = {31831056}, url = {https://doi.org/10.1186/s13195-019-0559-z} } @article{bitan2019-31699321, author = {Bitan, Gal}, title = {{Disease-modifying therapy for proteinopathies: Can the exception become the rule?}}, journal = {Progress in molecular biology and translational science}, year = {2019}, doi = {10.1016/bs.pmbts.2019.07.010}, pmid = {31699321}, url = {https://doi.org/10.1016/bs.pmbts.2019.07.010} } @article{cummings2019-31334330, author = {Cummings, J. and Lee, G. and Ritter, A. and Sabbagh, M. and Zhong, K.}, title = {{Alzheimer's disease drug development pipeline: 2019}}, journal = {Alzheimer's \& dementia (New York, N. Y.)}, year = {2019}, doi = {10.1016/j.trci.2019.05.008}, pmid = {31334330}, url = {https://doi.org/10.1016/j.trci.2019.05.008} } @article{foroutan2019-30904037, author = {Foroutan, N. and Hopkins, R. B. and Tarride, J. E. and Florez, I. D. and Levine, M.}, title = {{Safety and efficacy of active and passive immunotherapy in mild-to-moderate Alzheimer's disease: A systematic review and network meta-analysis}}, journal = {Clinical and investigative medicine. Medecine clinique et experimentale}, year = {2019}, doi = {10.25011/cim.v42i1.32393}, pmid = {30904037}, url = {https://doi.org/10.25011/cim.v42i1.32393} } @article{pradier2018-30486882, author = {Pradier, L. and Blanchard-Brégeon, V. and Bohme, A. and Debeir, T. and Menager, J. and Benoit, P. and Barneoud, P. and Taupin, V. and others}, title = {{SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA)}}, journal = {Alzheimer's research \& therapy}, year = {2018}, doi = {10.1186/s13195-018-0447-y}, pmid = {30486882}, url = {https://doi.org/10.1186/s13195-018-0447-y} } @article{willis2018-30511011, author = {Willis, Brian A and Sundell, Karen and Lachno, D Richard and Ferguson-Sells, Lisa R and Case, Michael G and Holdridge, Karen and DeMattos, Ronald B and Raskin, Joel and others}, title = {{Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia}}, journal = {Alzheimer's \& dementia (New York, N. Y.)}, year = {2018}, doi = {10.1016/j.trci.2018.10.001}, pmid = {30511011}, url = {https://doi.org/10.1016/j.trci.2018.10.001} } @article{arnold2018-30014506, author = {Arnold, Steven E and Betensky, Rebecca A}, title = {{Multicrossover Randomized Controlled Trial Designs in Alzheimer Disease}}, journal = {Annals of neurology}, year = {2018}, doi = {10.1002/ana.25280}, pmid = {30014506}, url = {https://doi.org/10.1002/ana.25280} } @article{arndt2018-29686315, author = {Arndt, J. W. and Qian, F. and Smith, B. A. and Quan, C. and Kilambi, K. P. and Bush, M. W. and Walz, T. and Pepinsky, R. B. and others}, title = {{Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β}}, journal = {Scientific reports}, year = {2018}, doi = {10.1038/s41598-018-24501-0}, pmid = {29686315}, url = {https://doi.org/10.1038/s41598-018-24501-0} } @article{haeberlein2018-12a02583, author = {Haeberlein, Samantha Budd and Gheuens, Sarah and Chen, Tianle and O'Gorman, John T. and von Rosenstiel, Philipp and Chiao, Ping and Wang, Guanfang and von Hehn, Christian and others}, title = {{Aducanumab 36-month data from PRIME: a randomized, double-blind, placebo-controlled Phase 1b study in patients with prodromal or mild Alzheimer’s disease (S2.004)}}, journal = {Neurology}, year = {2018}, doi = {10.1212/wnl.90.15_supplement.s2.004}, url = {https://doi.org/10.1212/wnl.90.15_supplement.s2.004} } @article{brashear2018-30412493, author = {Brashear, H. R. and Ketter, N. and Bogert, J. and Di, J. and Salloway, S. P. and Sperling, R.}, title = {{Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies}}, journal = {Journal of Alzheimer's disease : JAD}, year = {2018}, doi = {10.3233/jad-180675}, pmid = {30412493}, url = {https://doi.org/10.3233/jad-180675} } @article{salloway2018-29914022, author = {Salloway, S. P. and Sperling, R. and Fox, N. C. and Sabbagh, M. N. and Honig, L. S. and Porsteinsson, A. P. and Rofael, H. and Ketter, N. and others}, title = {{Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer's Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study}}, journal = {Journal of Alzheimer's disease : JAD}, year = {2018}, doi = {10.3233/jad-171157}, pmid = {29914022}, url = {https://doi.org/10.3233/jad-171157} } @article{salloway2018-30129411, author = {Salloway, S. and Marshall, G. A. and Lu, M. and Brashear, H. R.}, title = {{Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer's Disease: A Phase 2, Open-Label Extension Study}}, journal = {Current Alzheimer research}, year = {2018}, doi = {10.2174/1567205015666180821114813}, pmid = {30129411}, url = {https://doi.org/10.2174/1567205015666180821114813} } @article{mo2017-29296624, author = {Mo, J. J. and Li, J. Y. and Yang, Z. and Liu, Z. and Feng, J. S.}, title = {{Efficacy and safety of anti-amyloid- β immunotherapy for Alzheimer's disease: a systematic review and network meta-analysis}}, journal = {Annals of clinical and translational neurology}, year = {2017}, doi = {10.1002/acn3.469}, pmid = {29296624}, url = {https://doi.org/10.1002/acn3.469} } @article{panza2018-29037101, author = {Panza, Francesco and Seripa, Davide and Lozupone, Madia and Solfrizzi, Vincenzo and Imbimbo, Bruno P and Barulli, Maria Rosaria and Tortelli, Rosanna and Capozzo, Rosa and others}, title = {{The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset}}, journal = {Expert opinion on biological therapy}, year = {2018}, doi = {10.1080/14712598.2018.1389885}, pmid = {29037101}, url = {https://doi.org/10.1080/14712598.2018.1389885} } @article{vandyck2018-28967385, author = {van Dyck, C. H.}, title = {{Anti-Amyloid-β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise}}, journal = {Biological psychiatry}, year = {2018}, doi = {10.1016/j.biopsych.2017.08.010}, pmid = {28967385}, url = {https://doi.org/10.1016/j.biopsych.2017.08.010} } @article{shimada2017-28739983, author = {Shimada, Hiroyuki and Shoji, Mikio and Ikeuchi, Takeshi and Suzuki, Kazushi and Senda, Michio and Ishii, Kenji and Matsuda, Hiroshi and Iwata, Atsushi and others}, title = {{[DIAN/DIAN-J/DIAN-TU]}}, journal = {Brain and nerve = Shinkei kenkyu no shinpo}, year = {2017}, doi = {10.11477/mf.1416200811}, pmid = {28739983}, url = {https://doi.org/10.11477/mf.1416200811} } @article{gold2017-29067346, author = {Gold, Michael}, title = {{Phase II clinical trials of anti-amyloid β antibodies: When is enough, enough?}}, journal = {Alzheimer's \& dementia (New York, N. Y.)}, year = {2017}, doi = {10.1016/j.trci.2017.04.005}, pmid = {29067346}, url = {https://doi.org/10.1016/j.trci.2017.04.005} } @article{relkin2017-28381506, author = {Relkin, Norman R and Thomas, Ronald G and Rissman, Robert A and Brewer, James B and Rafii, Michael S and van Dyck, Christopher H and Jack, Clifford R and Sano, Mary and others}, title = {{A phase 3 trial of IV immunoglobulin for Alzheimer disease}}, journal = {Neurology}, year = {2017}, doi = {10.1212/wnl.0000000000003904}, pmid = {28381506}, url = {https://doi.org/10.1212/wnl.0000000000003904} } @article{ketter2017-28269765, author = {Ketter, N. and Brashear, H. R. and Bogert, J. and Di, J. and Miaux, Y. and Gass, A. and Purcell, D. D. and Barkhof, F. and others}, title = {{Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients}}, journal = {Journal of Alzheimer's disease : JAD}, year = {2017}, doi = {10.3233/jad-160216}, pmid = {28269765}, url = {https://doi.org/10.3233/jad-160216} } @article{buddhaeberlein2017-29181491, author = {Budd Haeberlein, S. and O'Gorman, J. and Chiao, P. and Bussière, T. and von Rosenstiel, P. and Tian, Y. and Zhu, Y. and von Hehn, C. and others}, title = {{Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease}}, journal = {The journal of prevention of Alzheimer's disease}, year = {2017}, doi = {10.14283/jpad.2017.39}, pmid = {29181491}, url = {https://doi.org/10.14283/jpad.2017.39} } @article{penninkilampi2017-28025724, author = {Penninkilampi, R. and Brothers, H. M. and Eslick, G. D.}, title = {{Safety and Efficacy of Anti-Amyloid-β Immunotherapy in Alzheimer's Disease: A Systematic Review and Meta-Analysis}}, journal = {Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology}, year = {2017}, doi = {10.1007/s11481-016-9722-5}, pmid = {28025724}, url = {https://doi.org/10.1007/s11481-016-9722-5} } @article{kastanenka2016-aa97eb96, author = {Kastanenka, Ksenia V. and Bussiere, Thierry and Shakerdge, Naomi and Qian, Fang and Weinreb, Paul H. and Rhodes, Ken and Bacskai, Brian J.}, title = {{Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice}}, journal = {The Journal of Neuroscience}, year = {2016}, doi = {10.1523/jneurosci.2080-16.2016}, url = {https://doi.org/10.1523/jneurosci.2080-16.2016} } @article{cummings2016-29067309, author = {Cummings, Jeffrey and Morstorf, Travis and Lee, Garam}, title = {{Alzheimer's drug-development pipeline: 2016}}, journal = {Alzheimer's \& dementia (New York, N. Y.)}, year = {2016}, doi = {10.1016/j.trci.2016.07.001}, pmid = {29067309}, url = {https://doi.org/10.1016/j.trci.2016.07.001} } @article{blaettler2016-916a25c5, author = {Blaettler, Thomas and Smith, Janice and Smith, Jillian P. and Paul, Robert H. and Asnaghi, Veronica and Fuji, Reina N. and Quartino, Angelica Linnea and Honigberg, Lee A. and others}, title = {{P2‐003: Clinical Trial Design of Cread: A Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group Phase 3 Study to Evaluate Crenezumab Treatment in Patients with Prodromal‐To‐Mild Alzheimer’s Disease}}, journal = {Alzheimer s \& Dementia}, year = {2016}, doi = {10.1016/j.jalz.2016.06.1207}, url = {https://doi.org/10.1016/j.jalz.2016.06.1207} } @article{ferrero2016-29067304, author = {Ferrero, J. and Williams, L. and Stella, H. and Leitermann, K. and Mikulskis, A. and O'Gorman, J. and Sevigny, J.}, title = {{First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease}}, journal = {Alzheimer's \& dementia (New York, N. Y.)}, year = {2016}, doi = {10.1016/j.trci.2016.06.002}, pmid = {29067304}, url = {https://doi.org/10.1016/j.trci.2016.06.002} } @article{loureiro2016-27131092, author = {Loureiro, J. A. and Gomes, B. and Fricker, G. and Coelho, M. A. N. and Rocha, S. and Pereira, M. C.}, title = {{Cellular uptake of PLGA nanoparticles targeted with anti-amyloid and anti-transferrin receptor antibodies for Alzheimer's disease treatment}}, journal = {Colloids and surfaces. B, Biointerfaces}, year = {2016}, doi = {10.1016/j.colsurfb.2016.04.041}, pmid = {27131092}, url = {https://doi.org/10.1016/j.colsurfb.2016.04.041} } @article{logovinsky2016-27048170, author = {Logovinsky, V. and Satlin, A. and Lai, R. and Swanson, C. and Kaplow, J. and Osswald, G. and Basun, H. and Lannfelt, L.}, title = {{Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody}}, journal = {Alzheimer's research \& therapy}, year = {2016}, doi = {10.1186/s13195-016-0181-2}, pmid = {27048170}, url = {https://doi.org/10.1186/s13195-016-0181-2} } @article{viglietta2016-5b6a5200, author = {Viglietta, Vissia and O'Gorman, John T. and Williams, Leslie J. and Tian, Ying and Sandrock, Alfred W. and Doody, Rachelle Smith and Salloway, Stephen and Barkhof, Frederik and others}, title = {{Randomized, Double-Blind, Placebo-Controlled Studies to Evaluate Treatment with Aducanumab (BIIB037) in Patients with Early Alzheimer’s Disease: Phase 3 Study Design (S1.003)}}, journal = {Neurology}, year = {2016}, doi = {10.1212/wnl.86.16_supplement.s1.003}, url = {https://doi.org/10.1212/wnl.86.16_supplement.s1.003} } @article{carlson2016-27239538, author = {Carlson, C. and Siemers, E. and Hake, A. and Case, M. and Hayduk, R. and Suhy, J. and Oh, J. and Barakos, J.}, title = {{Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease}}, journal = {Alzheimer's \& dementia (Amsterdam, Netherlands)}, year = {2016}, doi = {10.1016/j.dadm.2016.02.004}, pmid = {27239538}, url = {https://doi.org/10.1016/j.dadm.2016.02.004} } @article{piazza2016-27031492, author = {Piazza, F. and Winblad, B.}, title = {{Amyloid-Related Imaging Abnormalities (ARIA) in Immunotherapy Trials for Alzheimer's Disease: Need for Prognostic Biomarkers?}}, journal = {Journal of Alzheimer's disease : JAD}, year = {2016}, doi = {10.3233/jad-160122}, pmid = {27031492}, url = {https://doi.org/10.3233/jad-160122} } @article{delnomdedieu2016-26925577, author = {Delnomdedieu, M. and Duvvuri, S. and Li, D. J. and Atassi, N. and Lu, M. and Brashear, H. R. and Liu, E. and Ness, S. and others}, title = {{First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease}}, journal = {Alzheimer's research \& therapy}, year = {2016}, doi = {10.1186/s13195-016-0177-y}, pmid = {26925577}, url = {https://doi.org/10.1186/s13195-016-0177-y} } @article{shimada2016-27025079, author = {Shimada, Hiroyuki}, title = {{[Significance and progress of DIAN/A4/API]}}, journal = {Nihon rinsho. Japanese journal of clinical medicine}, year = {2016}, pmid = {27025079} } @article{ketter2016-29199321, author = {Ketter, N. and Liu, E. and Di, J. and Honig, L. S. and Lu, M. and Novak, G. and Werth, J. and LePrince Leterme, G. and others}, title = {{A Randomized, Double-Blind, Phase 2 Study of the Effects of the Vaccine Vanutide Cridificar with QS-21 Adjuvant on Immunogenicity, Safety and Amyloid Imaging in Patients with Mild to Moderate Alzheimer's Disease}}, journal = {The journal of prevention of Alzheimer's disease}, year = {2016}, doi = {10.14283/jpad.2016.118}, pmid = {29199321}, url = {https://doi.org/10.14283/jpad.2016.118} } @article{difrancesco2015-26441825, author = {DiFrancesco, J. C. and Longoni, M. and Piazza, F.}, title = {{Anti-Aβ Autoantibodies in Amyloid Related Imaging Abnormalities (ARIA): Candidate Biomarker for Immunotherapy in Alzheimer's Disease and Cerebral Amyloid Angiopathy}}, journal = {Frontiers in neurology}, year = {2015}, doi = {10.3389/fneur.2015.00207}, pmid = {26441825}, url = {https://doi.org/10.3389/fneur.2015.00207} } @article{siemers2016-26238576, author = {Siemers, E. R. and Sundell, K. L. and Carlson, C. and Case, M. and Sethuraman, G. and Liu-Seifert, H. and Dowsett, S. A. and Pontecorvo, M. J. and others}, title = {{Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients}}, journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association}, year = {2016}, doi = {10.1016/j.jalz.2015.06.1893}, pmid = {26238576}, url = {https://doi.org/10.1016/j.jalz.2015.06.1893} } @article{lasser2015-f0473682, author = {Lasser, Robert A. and Ostrowitzki, Susanne and Scheltens, Philip and Boada, Merçé and Dubois, Bruno and Dorflinger, Ernest E. and Balas, Bogdan and Nikolcheva, Tania and others}, title = {{DT‐01‐03: Efficacy and safety of gantenerumab in prodromal Alzheimer's disease: Results from scarlet road—a global, multicenter trial}}, journal = {Alzheimer s \& Dementia}, year = {2015}, doi = {10.1016/j.jalz.2015.08.153}, url = {https://doi.org/10.1016/j.jalz.2015.08.153} } @article{sevigny2015-204cb97e, author = {Sevigny, Jeff and Chiao, Ping and Williams, Leslie J. and Chen, Tianle and Ling, Yan and O'Gorman, John and Höck, Christoph and Nitsch, Roger M. and others}, title = {{O4‐04‐05: Aducanumab (BIIB037), an anti‐amyloid beta monoclonal antibody, in patients with prodromal or mild Alzheimer's disease: Interim results of a randomized, double‐blind, placebo‐controlled, phase 1b study}}, journal = {Alzheimer s \& Dementia}, year = {2015}, doi = {10.1016/j.jalz.2015.07.367}, url = {https://doi.org/10.1016/j.jalz.2015.07.367} } @article{hornberger2015-26231002, author = {Hornberger, John and Michalopoulos, Steven and Dai, Minghan and Andrade, Paula and Dilla, Tatiana and Happich, Michael}, title = {{Cost-Effectiveness of Florbetapir-PET in Alzheimer's Disease: A Spanish Societal Perspective}}, journal = {The journal of mental health policy and economics}, year = {2015}, pmid = {26231002} } @article{farlow2015-25918556, author = {Farlow, M. R. and Andreasen, N. and Riviere, M. E. and Vostiar, I. and Vitaliti, A. and Sovago, J. and Caputo, A. and Winblad, B. and others}, title = {{Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease}}, journal = {Alzheimer's research \& therapy}, year = {2015}, doi = {10.1186/s13195-015-0108-3}, pmid = {25918556}, url = {https://doi.org/10.1186/s13195-015-0108-3} } @article{toyn2015-25860157, author = {Toyn, Jeremy}, title = {{What lessons can be learned from failed Alzheimer's disease trials?}}, journal = {Expert review of clinical pharmacology}, year = {2015}, doi = {10.1586/17512433.2015.1034690}, pmid = {25860157}, url = {https://doi.org/10.1586/17512433.2015.1034690} } @article{andreasen2015-25789616, author = {Andreasen, N. and Simeoni, M. and Ostlund, H. and Lisjo, P. I. and Fladby, T. and Loercher, A. E. and Byrne, G. J. and Murray, F. and others}, title = {{First administration of the Fc-attenuated anti-β amyloid antibody GSK933776 to patients with mild Alzheimer's disease: a randomized, placebo-controlled study}}, journal = {PloS one}, year = {2015}, doi = {10.1371/journal.pone.0098153}, pmid = {25789616}, url = {https://doi.org/10.1371/journal.pone.0098153} } @article{arrighi2016-25669746, author = {Arrighi, H. M. and Barakos, J. and Barkhof, F. and Tampieri, D. and Jack, C. and Melançon, D. and Morris, K. and Ketter, N. and others}, title = {{Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis}}, journal = {Journal of neurology, neurosurgery, and psychiatry}, year = {2016}, doi = {10.1136/jnnp-2014-309493}, pmid = {25669746}, url = {https://doi.org/10.1136/jnnp-2014-309493} } @article{yang2015-25860060, author = {Yang, C. and Xiao, S.}, title = {{New developments of clinical trial in immunotherapy for Alzheimer's disease}}, journal = {Current pharmaceutical biotechnology}, year = {2015}, doi = {10.2174/138920101606150407112319}, pmid = {25860060}, url = {https://doi.org/10.2174/138920101606150407112319} } @article{boncoraglio2015-25537009, author = {Boncoraglio, G. B. and Piazza, F. and Savoiardo, M. and Farina, L. and DiFrancesco, J. C. and Prioni, S. and Tagliavini, F. and Parati, E. A. and others}, title = {{Prodromal Alzheimer's disease presenting as cerebral amyloid angiopathy-related inflammation with spontaneous amyloid-related imaging abnormalities and high cerebrospinal fluid anti-Aβ autoantibodies}}, journal = {Journal of Alzheimer's disease : JAD}, year = {2015}, doi = {10.3233/jad-142376}, pmid = {25537009}, url = {https://doi.org/10.3233/jad-142376} } @article{ryan2015-25408217, author = {Ryan, N. S. and Lashley, T. and Revesz, T. and Dantu, K. and Fox, N. C. and Morris, H. R.}, title = {{Spontaneous ARIA (amyloid-related imaging abnormalities) and cerebral amyloid angiopathy related inflammation in presenilin 1-associated familial Alzheimer's disease}}, journal = {Journal of Alzheimer's disease : JAD}, year = {2015}, doi = {10.3233/jad-142325}, pmid = {25408217}, url = {https://doi.org/10.3233/jad-142325} } @article{relkin2014-25546751, author = {Relkin, Norman R.}, title = {{Intravenous immunoglobulin for Alzheimer's disease}}, journal = {Clinical \& Experimental Immunology}, year = {2014}, doi = {10.1111/cei.12500}, pmid = {25546751}, url = {https://doi.org/10.1111/cei.12500} } @article{panza2014-25081412, author = {Panza, Francesco and Solfrizzi, Vincenzo and Imbimbo, Bruno P and Giannini, Michele and Santamato, Andrea and Seripa, Davide and Logroscino, Giancarlo}, title = {{Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease}}, journal = {Expert review of neurotherapeutics}, year = {2014}, doi = {10.1586/14737175.2014.945522}, pmid = {25081412}, url = {https://doi.org/10.1586/14737175.2014.945522} } @article{cummings2014-25024750, author = {Cummings, J. L. and Morstorf, T. and Zhong, K.}, title = {{Alzheimer's disease drug-development pipeline: few candidates, frequent failures}}, journal = {Alzheimer's research \& therapy}, year = {2014}, doi = {10.1186/alzrt269}, pmid = {25024750}, url = {https://doi.org/10.1186/alzrt269} } @article{cummings2014-a7c335d7, author = {Cummings, Jeffrey L. and Cho, William and Ward, Michael Emmerson and Friesenhahn, Michel J. and Brunstein, Flávia and Honigberg, Lee A. and Clayton, David and Mortensen, Deborah L. and others}, title = {{O4‐11‐06: A RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CRENEZUMAB IN PATIENTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE}}, journal = {Alzheimer s \& Dementia}, year = {2014}, doi = {10.1016/j.jalz.2014.04.450}, url = {https://doi.org/10.1016/j.jalz.2014.04.450} } @article{lannfelt2014-25031633, author = {Lannfelt, L. and Möller, C. and Basun, H. and Osswald, G. and Sehlin, D. and Satlin, A. and Logovinsky, V. and Gellerfors, P.}, title = {{Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease}}, journal = {Alzheimer's research \& therapy}, year = {2014}, doi = {10.1186/alzrt246}, pmid = {25031633}, url = {https://doi.org/10.1186/alzrt246} } @article{stamour2014-24655894, author = {St-Amour, I. and Paré, I. and Tremblay, C. and Coulombe, K. and Bazin, R. and Calon, F.}, title = {{IVIg protects the 3xTg-AD mouse model of Alzheimer's disease from memory deficit and Aβ pathology}}, journal = {Journal of neuroinflammation}, year = {2014}, doi = {10.1186/1742-2094-11-54}, pmid = {24655894}, url = {https://doi.org/10.1186/1742-2094-11-54} } @article{lannfelt2014-24605809, author = {Lannfelt, L. and Relkin, N. R. and Siemers, E. R.}, title = {{Amyloid-ß-directed immunotherapy for Alzheimer's disease}}, journal = {Journal of internal medicine}, year = {2014}, doi = {10.1111/joim.12168}, pmid = {24605809}, url = {https://doi.org/10.1111/joim.12168} } @article{golde2014-24393284, author = {Golde, T. E.}, title = {{Open questions for Alzheimer's disease immunotherapy}}, journal = {Alzheimer's research \& therapy}, year = {2014}, doi = {10.1186/alzrt233}, pmid = {24393284}, url = {https://doi.org/10.1186/alzrt233} } @article{novakovic2013-24255592, author = {Novakovic, Dijana and Feligioni, Marco and Scaccianoce, Sergio and Caruso, Alessandra and Piccinin, Sonia and Schepisi, Chiara and Errico, Francesco and Mercuri, Nicola B and others}, title = {{Profile of gantenerumab and its potential in the treatment of Alzheimer's disease}}, journal = {Drug design, development and therapy}, year = {2013}, doi = {10.2147/dddt.s53401}, pmid = {24255592}, url = {https://doi.org/10.2147/dddt.s53401} } @article{shimada2013-24101429, author = {Shimada, Hiroyuki}, title = {{[The DIAN study]}}, journal = {Brain and nerve = Shinkei kenkyu no shinpo}, year = {2013}, pmid = {24101429} } @article{vellas2013-23809364, author = {Vellas, B. and Carrillo, M. C. and Sampaio, C. and Brashear, H. R. and Siemers, E. and Hampel, H. and Schneider, L. S. and Weiner, M. and others}, title = {{Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force}}, journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association}, year = {2013}, doi = {10.1016/j.jalz.2013.03.007}, pmid = {23809364}, url = {https://doi.org/10.1016/j.jalz.2013.03.007} } @article{pradier2013-c5f3311d, author = {Pradier, Laurent and Cohen, Caroline and Blanchard, Veronique and Debeir, Thomas and Barnéoud, Pascal and Canton, Thierry and Ménager, Jean and Bohme, Andrees and others}, title = {{P4–285: SAR228810: An antiprotofibrillar beta‐amyloid antibody designed to reduce risk of amyloid‐related imaging abnormalities (ARIA)}}, journal = {Alzheimer s \& Dementia}, year = {2013}, doi = {10.1016/j.jalz.2013.05.1678}, url = {https://doi.org/10.1016/j.jalz.2013.05.1678} } @article{tesseur2013-23704554, author = {Tesseur, I. and Lo, A. C. and Roberfroid, A. and Dietvorst, S. and Van Broeck, B. and Borgers, M. and Gijsen, H. and Moechars, D. and others}, title = {{Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models"}}, journal = {Science (New York, N.Y.)}, year = {2013}, doi = {10.1126/science.1233937}, pmid = {23704554}, url = {https://doi.org/10.1126/science.1233937} } @article{piazza2013-23625526, author = {Piazza, F. and Greenberg, S. M. and Savoiardo, M. and Gardinetti, M. and Chiapparini, L. and Raicher, I. and Nitrini, R. and Sakaguchi, H. and others}, title = {{Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies}}, journal = {Annals of neurology}, year = {2013}, doi = {10.1002/ana.23857}, pmid = {23625526}, url = {https://doi.org/10.1002/ana.23857} } @article{tayeb2013-23574434, author = {Tayeb, H. O. and Murray, E. D. and Price, B. H. and Tarazi, F. I.}, title = {{Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive?}}, journal = {Expert opinion on biological therapy}, year = {2013}, doi = {10.1517/14712598.2013.789856}, pmid = {23574434}, url = {https://doi.org/10.1517/14712598.2013.789856} } @article{barkhof2013-23436056, author = {Barkhof, F. and Daams, M. and Scheltens, P. and Brashear, H. R. and Arrighi, H. M. and Bechten, A. and Morris, K. and McGovern, M. and others}, title = {{An MRI rating scale for amyloid-related imaging abnormalities with edema or effusion}}, journal = {AJNR. American journal of neuroradiology}, year = {2013}, doi = {10.3174/ajnr.a3475}, pmid = {23436056}, url = {https://doi.org/10.3174/ajnr.a3475} } @article{riedmann2012-22914446, author = {Riedmann, Eva M}, title = {{Two new combination pediatric vaccines advancing to use in infants}}, journal = {Human vaccines \& immunotherapeutics}, year = {2012}, doi = {10.4161/hv.21700}, pmid = {22914446}, url = {https://doi.org/10.4161/hv.21700} } @article{farlow2012-22672770, author = {Farlow, M. and Arnold, S. E. and van Dyck, C. H. and Aisen, P. S. and Snider, B. J. and Porsteinsson, A. P. and Friedrich, S. and Dean, R. A. and others}, title = {{Safety and biomarker effects of solanezumab in patients with Alzheimer's disease}}, journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association}, year = {2012}, doi = {10.1016/j.jalz.2011.09.224}, pmid = {22672770}, url = {https://doi.org/10.1016/j.jalz.2011.09.224} } @article{samadi2011-21504387, author = {Samadi, H. and Sultzer, D.}, title = {{Solanezumab for Alzheimer's disease}}, journal = {Expert opinion on biological therapy}, year = {2011}, doi = {10.1517/14712598.2011.578573}, pmid = {21504387}, url = {https://doi.org/10.1517/14712598.2011.578573} } @article{kerchner2010-20497044, author = {Kerchner, Geoffrey A and Boxer, Adam L}, title = {{Bapineuzumab}}, journal = {Expert opinion on biological therapy}, year = {2010}, doi = {10.1517/14712598.2010.493872}, pmid = {20497044}, url = {https://doi.org/10.1517/14712598.2010.493872} } @article{siemers2010-20375655, author = {Siemers, E. R. and Friedrich, S. and Dean, R. A. and Gonzales, C. R. and Farlow, M. R. and Paul, S. M. and Demattos, R. B.}, title = {{Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease}}, journal = {Clinical neuropharmacology}, year = {2010}, doi = {10.1097/wnf.0b013e3181cb577a}, pmid = {20375655}, url = {https://doi.org/10.1097/wnf.0b013e3181cb577a} } @article{risner2006-16446752, author = {Risner, M. E. and Saunders, A. M. and Altman, J. F. and Ormandy, G. C. and Craft, S. and Foley, I. M. and Zvartau-Hind, M. E. and Hosford, D. A. and others}, title = {{Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease}}, journal = {The pharmacogenomics journal}, year = {2006}, doi = {10.1038/sj.tpj.6500369}, pmid = {16446752}, url = {https://doi.org/10.1038/sj.tpj.6500369} } @article{petrovsky2004-15479434, author = {Petrovsky, N. and Aguilar, J. C.}, title = {{Vaccine adjuvants: current state and future trends}}, journal = {Immunology and cell biology}, year = {2004}, doi = {10.1111/j.0818-9641.2004.01272.x}, pmid = {15479434}, url = {https://doi.org/10.1111/j.0818-9641.2004.01272.x} } @article{hock2003-12765607, author = {Hock, C. and Konietzko, U. and Streffer, JR. and Tracy, J. and Signorell, A. and Müller-Tillmanns, B. and Lemke, U. and Henke, K. and others}, title = {{Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease}}, journal = {Neuron}, year = {2003}, doi = {10.1016/s0896-6273(03)00294-0}, pmid = {12765607}, url = {https://doi.org/10.1016/s0896-6273(03)00294-0} } @article{citron2002-12403985, author = {Citron, M.}, title = {{Alzheimer's disease: treatments in discovery and development}}, journal = {Nature neuroscience}, year = {2002}, doi = {10.1038/nn940}, pmid = {12403985}, url = {https://doi.org/10.1038/nn940} } @article{hyman2001-11409436, author = {Hyman, B. T. and Smith, C. and Buldyrev, I. and Whelan, C. and Brown, H. and Tang, M. X. and Mayeux, R.}, title = {{Autoantibodies to amyloid-beta and Alzheimer's disease}}, journal = {Annals of neurology}, year = {2001}, doi = {10.1002/ana.1061}, pmid = {11409436}, url = {https://doi.org/10.1002/ana.1061} } @article{molloy2000-10961441, author = {Molloy, D W and Standish, T I}, title = {{Clinical experience with Cerebrolysin}}, journal = {Journal of neural transmission. Supplementum}, year = {2000}, pmid = {10961441} }